Skip to main content
Research

Publications: Prof Peter Schmid

Bruzas S, Gluz O, Harbeck N, Schmid P, Cortés J, Blohmer J, Seiberling C, Chiari O et al. ( 2022 ) . Gene signatures in patients with early breast cancer and relapse despite pathologic complete response . npj Breast Cancer vol. 8 , ( 1 )
Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G et al. ( 2022 ) . Immunotherapy for early triple negative breast cancer: research agenda for the next decade . npj Breast Cancer vol. 8 , ( 1 )
Cortes J, Zhou X, Schmid P ( 2022 ) . Pembrolizumab in Triple-Negative Breast Cancer. Reply . The New England journal of medicine vol. 387 , ( 15 )
Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, Trédan O, Ciruelos E et al. ( 2022 ) . Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer . Journal of Clinical Oncology vol. 40 , ( 29 ) 3365 - 3376 .
Kim DW, Gadgeel S, Gettinger SN, Riely GJ, Oxnard GR, Mekhail T, Schmid P, Dowlati A et al. ( 2022 ) . Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC . JTO Clinical and Research Reports vol. 3 , ( 8 )
Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH et al. ( 2022 ) . Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer . New England Journal of Medicine vol. 387 , ( 3 ) 217 - 226 .
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT et al. ( 2022 ) . Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer . New England Journal of Medicine vol. 387 , ( 1 ) 9 - 20 .
Wu Y, Biswas D, Usaite I, Angelova M, Boeing S, Karasaki T, Veeriah S, Czyzewska-Khan J et al. ( 2022 ) . A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer . Nature Cancer vol. 3 , ( 6 ) 696 - 709 .
Schmid P, Cortes J, Dent R ( 2022 ) . Pembrolizumab in Early Triple-Negative Breast Cancer. Reply . The New England journal of medicine vol. 386 , ( 18 ) 1771 - 1772 .
Hall PE, Schmid P ( 2022 ) . Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies . Breast Cancer Research and Treatment vol. 193 , ( 1 ) 21 - 35 .
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C et al. ( 2022 ) . Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer . New England Journal of Medicine vol. 386 , ( 6 ) 556 - 567 .
Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS et al. ( 2021 ) . A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer . Breast Cancer Research vol. 23 , ( 1 )
Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A et al. ( 2021 ) . Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’: Annals of Oncology 2021; 32: 983-993 (Annals of Oncology (2021) 32(8) (983–993), (S0923753421015556), (10.1016/j.annonc.2021.05.355)) . Annals of Oncology vol. 32 , ( 12 )
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D et al. ( 2021 ) . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer <sup>☆</sup> . Annals of Oncology vol. 32 , ( 12 ) 1475 - 1495 .
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, Gavilá J, Sampayo-Cordero M et al. ( 2021 ) . Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2 -Negative Advanced Breast Cancer: A Randomized Clinical Trial . JAMA Oncology vol. 7 , ( 12 ) 1791 - 1799 .
Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, Möbus V, Cortes J et al. ( 2021 ) . Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study . npj Breast Cancer vol. 7 , ( 1 )
Schmid P ( 2021 ) . The use of immunotherapy in triple-negative breast cancer . Clinical Advances in Hematology and Oncology vol. 19 , ( 12 ) 770 - 773 .
Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A et al. ( 2021 ) . Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’(Annals of Oncology (2021) 32(8) (983–993), (S0923753421015556), (10.1016/j.annonc.2021.05.355)) . Annals of Oncology vol. 32 , ( 10 )
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z et al. ( 2021 ) . Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication . Annals of Oncology vol. 32 , ( 10 ) 1245 - 1255 .
Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH et al. ( 2021 ) . Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study . Journal of the National Cancer Institute vol. 113 , ( 8 ) 1005 - 1016 .
Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A et al. ( 2021 ) . First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis . Annals of Oncology vol. 32 , ( 8 ) 983 - 993 .
Cortes J, Rugo HS, Guo Z, Karantza V, Schmid P ( 2021 ) . Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply . The Lancet vol. 398 , ( 10294 ) 24 - 25 .
Emancipator K, Winer EP, Lipatov O, Im S-A, Goncalves A, Muñoz-Couselo E, Lee KS, Nowecki Z et al. ( 2021 ) . Contribution of tumour and immune cells to PD-L1 as a predictive biomarker in metastatic triple-negative breast cancer (mTNBC): analysis from keynote-119 . Pathology . vol. 53 , s47 - s48 .
Pérez-García JM, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Schmid P, Marmé F, Escrivá-de-Romani S et al. ( 2021 ) . Chemotherapy de-escalation using an <sup>18</sup>F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial . The Lancet Oncology vol. 22 , ( 6 ) 858 - 871 .
Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, Galván P, Dientsmann R et al. ( 2021 ) . Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer . European Journal of Cancer vol. 148 , 134 - 145 .
Pérez-García JM, Llombart-Cussac A, G. Cortés M, Curigliano G, López-Miranda E, Alonso JL, Bermejo B, Calvo L et al. ( 2021 ) . Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial . European Journal of Cancer vol. 148 , 382 - 394 .
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD et al. ( 2021 ) . Sacituzumab govitecan in metastatic triple-negative breast cancer . New England Journal of Medicine vol. 384 , ( 16 ) 1529 - 1541 .
Falchook G, Infante J, Arkenau HT, Patel MR, Dean E, Borazanci E, Brenner A, Cook N et al. ( 2021 ) . First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors . EClinicalMedicine vol. 34 ,
Winer EP, Lipatov O, Im SA, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Tamura K et al. ( 2021 ) . Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial . The Lancet Oncology vol. 22 , ( 4 ) 499 - 511 .
Rugo H, Llombart-Cussac A, Andre F, Robson ME, Saji S, Harbeck N, Schmid P, Cescon D et al. ( 2021 ) . Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) . Cancer Research . vol. 81 ,
Schmid P, Kockx M, Kim S-B, Wheatley D, Phillips MM, Hoffmann O, Blohmer JU, Im S-A et al. ( 2021 ) . Abstract PD14-06: Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER+ primary breast cancer . Cancer Research . vol. 81 ,
Bedard PL, Jhaveri K, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop IE et al. ( 2021 ) . A phase I/Ib study evaluating GDC-0077+palbociclib (palbo) plus fulvestrant in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC) . CANCER RESEARCH . vol. 81 ,
Varghese J, Gohari SS, Rizki H, Faheem I, Langridge B, Kümmel S, Johnson L, Schmid P ( 2021 ) . A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction . Breast vol. 55 , 55 - 62 .
Loi S, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS, De laurentiis M et al. ( 2021 ) . Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086 . CANCER RESEARCH . vol. 81 ,
Schmid P, Kockx M, Kim S-B, Wheatley D, Phillips MM, Hoffmann O, Blohmer JU, Im S-A et al. ( 2021 ) . Dynamic changes of PD-L1 and T-cell activation in ECLIPSE: A phase II study investigating preoperative immune combination strategies in untreated, operable ER plus primary breast cancer . CANCER RESEARCH . vol. 81 ,
Emens L, Molinero L, Adams S, Rugo HS, Schneeweiss A, Dieras V, Iwata H, Barrios C et al. ( 2021 ) . Genomic profiling and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: An exploratory analysis from the phase 3 IMpassion130 trial . CANCER RESEARCH . vol. 81 ,
Varghese JS, Gohari S, Shawky M, Hyun F, Johnson L, Schmid P ( 2021 ) . Impact of neoadjuvant chemotherapy on breast reconstruction - systematic review and meta-analysis . CANCER RESEARCH . vol. 81 ,
Schmid P, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, White S, Laliman V et al. ( 2021 ) . Molecular mechanism of ipatasertib (IPAT) and its combination with atezolizumab (atezo) in patients (pts) with locally advanced/metastatic triple-negative breast cancer (aTNBC) . CANCER RESEARCH . vol. 81 ,
Manuel Perez-Garcia J, Llombart-Cussac A, Bellet M, Dalenc F, Gil Gil MJ, Ruiz Borrego M, Gavila J, Sampayo-Cordero M et al. ( 2021 ) . Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL) . CANCER RESEARCH . vol. 81 ,
Winer E, Lipatov O, Im S-A, Goncalves A, Lee KS, Schmid P, Testa L, Witzel I et al. ( 2021 ) . Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases . CANCER RESEARCH . vol. 81 ,
Turner N, Jhaveri K, Kalinsky K, Loibl S, Loi S, Im S-A, Saura C, Schmid P et al. ( 2021 ) . Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC) . CANCER RESEARCH . vol. 81 ,
Jhaveri K, Juric D, Varga A, Turner N, Schmid P, Saura C, Oliveira M, Krop IE et al. ( 2021 ) . Preliminary correlative analysis of clinical outcomes with PIK3CA mutation (mut) status from a phase I/Ib study of GDC-0077 in patients (pts) with hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC) . CANCER RESEARCH . vol. 81 ,
Olivera M, Jhaveri K, Juric D, Bedard PL, Cervantes A, Gambardella V, Hamilton E, Italiano A et al. ( 2021 ) . Targeted safety events from a phase I/Ib study evaluating GDC-0077 alone and in combination with endocrine therapy (ET) +/- palbociclib (palbo) in patients (pts) with PIK3CA-mutant (mut), hormone receptor-positive/HER2-negative metastatic breast cancer (HR+/HER2-mBC) . CANCER RESEARCH . vol. 81 ,
Andre F, Hamilton E, Loi S, Schmid P, Yu T, Lu S, Boston S, D'Cruz C et al. ( 2021 ) . Trastuzumab deruxtecan (T-DXd; DS-8201) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2 open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07) . CANCER RESEARCH . vol. 81 ,
Jhaveri K, Hamilton E, Loi S, Schmid P, Darilay A, Gao C, Patel G, Wrona M et al. ( 2021 ) . Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with other anticancer agents in patients with HER2-low metastatic breast cancer: A phase 1b, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast08) . CANCER RESEARCH . vol. 81 ,
Varghese J, Gohari S, Faheem M, Kümmel S, Johnson L, Schmid P ( 2021 ) . A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction . European Journal of Surgical Oncology vol. 47 , ( 1 )
Hall PE, Schmid P ( 2021 ) . Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials . Expert Opinion on Emerging Drugs vol. 26 , ( 2 ) 131 - 147 .
Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, Briggs A, Hu P et al. ( 2020 ) . Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: A meta-analysis . Cancer Research vol. 80 , ( 24 ) 5427 - 5434 .
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O et al. ( 2020 ) . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial . The Lancet vol. 396 , ( 10265 ) 1817 - 1828 .
Verrill M, Wardley AM, Retzler J, Smith AB, Bottomley C, Ní Dhochartaigh S, Tran I, Leslie I et al. ( 2020 ) . Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage . Health and Quality of Life Outcomes vol. 18 , ( 1 )
Rugo HS, Loi S, Adams S, von Moos R, Schmid P, Schneeweiss A, Barrios CH, Iwata H et al. ( 2020 ) . Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): post-hoc analysis of IMpassion130 . SWISS MEDICAL WEEKLY . 31S - 31S .
Dent R, Cortes J, Pusztai L, McArthur HL, Kuemmel S, Bergh J, Denkert C, Park YH et al. ( 2020 ) . 1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) . Annals of Oncology vol. 31 , s1241 - s1242 .
Yusof MM, Cescon DW, Rugo HS, Im S-A, Gallardo C, Lipatov O, Barrios CH, Holgado E et al. ( 2020 ) . 43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia . Annals of Oncology vol. 31 ,
Im S-A, Cortes J, Lipatov O, Goncalves A, Lee K-S, Schmid P, Tamura K, Testa L et al. ( 2020 ) . 44O Pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-119 Asia-Pacific subpopulation . Annals of Oncology . vol. 31 ,
Iwata H, Emens L, Adams S, Barrios CH, Diéras V, Loi S, Rugo HS, Schneeweiss A et al. ( 2020 ) . 49MO IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer . Annals of Oncology vol. 31 , s1261 - s1262 .
Saji S, Cussac AL, Andre F, Robson ME, Harbeck N, Schmid P, Cescon DW, Ahn JS et al. ( 2020 ) . 68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC . Annals of Oncology vol. 31 ,
Harder H, Shilling VM, May SF, Cella D, Schmid P, Fallowfield LJ ( 2020 ) . The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer . Breast Cancer Research and Treatment vol. 183 , ( 3 ) 629 - 638 .
Emens LA, Adams S, Barrios CH, Dieras VC, Iwata H, Loi S, Rugo HS, Schneeweiss A et al. ( 2020 ) . IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer . Annals of Oncology vol. 31 ,
Rugo HS, Cussac AL, André F, Robson M, Saji S, Harbeck N, Schmid P, Cescon DW et al. ( 2020 ) . A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009 . Annals of Oncology vol. 31 ,
Martínez SG, Mies BP, Casas TC, Rosa JMR, Peralto JLR, Curigliano G, Schmid P, Kümmel S et al. ( 2020 ) . Differences in the mutational profile between primary breast carcinomas and their cutaneous metastasis . Annals of Oncology . vol. 31 ,
Bruzas S, Kümmel S, Harbeck N, Schmid P, Cortés J, Seiberling C, Chiari O, Harrach H et al. ( 2020 ) . Gene expression in early breast cancer (EBC) patients (pts) with relapse despite pathologic complete response (pCR): An intra- and interindividual (matched control) analysis . Annals of Oncology vol. 31 ,
Kaufman PA, Martin M, Mayer I, Vahdat LT, Simon SP, Schmid P, McArthur HL, Dent R et al. ( 2020 ) . International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS) . Annals of Oncology vol. 31 , s394 - s395 .
Gambardella V, Cervantes A, Bedard PL, Hamilton EP, Italiano A, Jhaveri K, Juric D, Kalinsky K et al. ( 2020 ) . PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2– BC) . Annals of Oncology . vol. 31 , s381 - s382 .
Turner N, Jhaveri K, Kalinsky K, Loibl S, Loi S, Im S-A, Saura C, Schmid P et al. ( 2020 ) . Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2– LA/MBC) . Annals of Oncology . vol. 31 , s391 - s392 .
Emens LA, Molinero L, Adams S, Rugo HS, Schneeweiss A, Diéras V, Iwata H, Barrios CH et al. ( 2020 ) . Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial . Annals of Oncology vol. 31 , s360 - s361 .
Robertson JFR, Evans A, Henschen S, Kirwan CC, Jahan A, Kenny LM, Dixon JM, Schmid P et al. ( 2020 ) . A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer . Clinical Cancer Research vol. 26 , ( 16 )
Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S, Briggsl A, Karantza V et al. ( 2020 ) . Evaluation of pathologic complete response as a surrogate for long-term survival outcomes in triple-negative breast cancer . JNCCN Journal of the National Comprehensive Cancer Network vol. 18 , ( 8 ) 1096 - 1104 .
AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, Lund T, Moore DA et al. ( 2020 ) . Geospatial immune variability illuminates differential evolution of lung adenocarcinoma . Nature Medicine vol. 26 , ( 7 ) 1054 - 1062 .
Schmid P, K?mmel S, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, White S et al. ( 2020 ) . Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC) . Geburtshilfe und Frauenheilkunde vol. 80 , ( 06 ) e44 - e45 .
Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, Boeing S, Krzystanek M et al. ( 2020 ) . Publisher Correction: A clonal expression biomarker associates with lung cancer mortality (Nature Medicine, (2019), 25, 10, (1540-1548), 10.1038/s41591-019-0595-z) . Nature Medicine vol. 26 , ( 7 )
Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA et al. ( 2020 ) . Publisher Correction: Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse (Nature Medicine, (2019), 25, 10, (1534-1539), 10.1038/s41591-019-0593-1) . Nature Medicine vol. 26 , ( 7 )
Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, Hatipoglu E, Oakes T et al. ( 2020 ) . Publisher Correction: Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer (Nature Medicine, (2019), 25, 10, (1549-1559), 10.1038/s41591-019-0592-2) . Nature Medicine vol. 26 , ( 7 )
Schmid P, Dent R, O'Shaughnessy J ( 2020 ) . Pembrolizumab for Early Triple-Negative Breast Cancer. Reply . The New England journal of medicine vol. 382 , ( 26 )
Schmid P, K?mmel S, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, White S et al. ( 2020 ) . Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC) . Senologie - Zeitschrift für Mammadiagnostik und -therapie . Conference: 40. Jahrestagung der Deutschen Gesellschaft für Senologie e.V. vol. 17 , e26 - e27 .
Schmid P, Cortes J, Robson ME, Iwata H, Hegg R, Nechaeva M, Xu B, Verma S et al. ( 2020 ) . A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) tps1109 - tps1109 .
Winer EP, Lipatov O, Im S-A, Goncalves A, Muñoz-Couselo E, Lee KS, Schmid P, Testa L et al. ( 2020 ) . Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119 . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 1013 - 1013 .
Cortes J, Gebhart G, Ruiz Borrego M, Stradella A, Bermejo B, Escrivá S, Calvo Martínez L, Ribelles N et al. ( 2020 ) . Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 503 - 503 .
Rugo HS, Llombart-Cussac A, Andre F, Robson ME, Saji S, Harbeck N, Schmid P, Cescon DW et al. ( 2020 ) . KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) tps596 - tps596 .
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O et al. ( 2020 ) . KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 1000 - 1000 .
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz Borrego M, Gavilá J, Sampayo-Cordero M et al. ( 2020 ) . PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) 1007 - 1007 .
Conte PF, Dieci MV, Bisagni G, De Laurentiis M, Tondini CA, Schmid P, De Salvo GL, Moratello G et al. ( 2020 ) . Phase III randomized study of adjuvant treatment with the ANTI-PD-L1 antibody avelumab for high-risk triple negative breast cancer patients: The A-BRAVE trial . Journal of Clinical Oncology vol. 38 , ( 15_suppl ) tps598 - tps598 .
Schmid-Araya JM, Schmid PE, Majdi N, Traunspurger W ( 2020 ) . Biomass and production of freshwater meiofauna: a review and a new allometric model . Hydrobiologia vol. 847 , ( 12 ) 2681 - 2703 .
Schmid P, Haiderali A, Mejia J, Guo Z, Zhou X, Martin-Nguyen A, Cortés J, Winer E ( 2020 ) . 141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer . Annals of Oncology . vol. 31 , s65 - s66 .
Schmid P, Rugo HS, Cortés J, Blum P, Crossley K, Massey D, Burris HA ( 2020 ) . 181TiP Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement (XENERA™-1) . Annals of Oncology . vol. 31 ,
Hirshfield K, Cardoso F, Bardia A, Andre F, Cescon D, McArthur H, Telli M, Loi S et al. ( 2020 ) . KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for High-Risk, Early-Stage, ER+/HER2-Breast Cancer . ANNALS OF SURGICAL ONCOLOGY . vol. 27 , S288 - S288 .
Adams S, Diéras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S et al. ( 2020 ) . Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer . Annals of Oncology vol. 31 , ( 5 ) 582 - 589 .
Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T et al. ( 2020 ) . Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study . Annals of Oncology vol. 31 , ( 5 ) 569 - 581 .
Schmid PE, Schmid-Araya JM, Tokeshi M ( 2020 ) . The scaling of biomass variance across trophic levels in stream species communities: a macroecological approach . Hydrobiologia vol. 847 , ( 12 ) 2705 - 2723 .
Burrell RA, Kumar SS, Kateb A, Dougall G, Wulff J, Benson J, Forouhi P, Agrawal A et al. ( 2020 ) . PIONEER: pre-operative window study of letrozole plus progesterone receptor agonist megestrol acetate versus letrozole alone in post-menopausal patients with oestrogen receptor-positive breast cancer . BREAST CANCER RESEARCH AND TREATMENT . vol. 180 , 542 - 542 .
Schmid P, Cortes L, Pusztai L ( 2020 ) . Pembrolizumab plus Neoadjuvant Chemotherapy Improves Pathologic Complete Response Rates in Triple-Negative Breast Cancer . Journal of Clinical Outcomes Management vol. 27 , ( 2 ) 53 - 55 .
Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q et al. ( 2020 ) . TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer . Future Oncology vol. 16 , ( 12 ) 705 - 712 .
Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F, Barrios CH, Wagle S et al. ( 2020 ) . Enhancing global access to cancer medicines . CA Cancer Journal for Clinicians vol. 70 , ( 2 ) 105 - 124 .
López S, Lim EL, Horswell S, Haase K, Huebner A, Dietzen M, Mourikis TP, Watkins TBK et al. ( 2020 ) . Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution . Nature Genetics vol. 52 , ( 3 ) 283 - 293 .
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH et al. ( 2020 ) . Pembrolizumab for early triple-negative breast cancer . New England Journal of Medicine vol. 382 , ( 9 ) 810 - 821 .
Rugo HS, Bardia A, Tolaney SM, Arteaga C, Cortes J, Sohn J, Marmé F, Hong Q et al. ( 2020 ) . Abstract OT1-07-05: TROPiCS-02: phase 3 study of Sacituzumab Govitecan (IMMU-132) in relapsed/refractory hormonal receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC) . Cancer Research . vol. 80 ,
Juric D, Kalinsky K, Oliveira M, Cervantes A, Bedard P, Krop I, Hamilton E, Schmid P et al. ( 2020 ) . Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA -mutant solid tumors . Cancer Research . vol. 80 ,
Kaufmann P, Cortes J, Martin M, Mayer I, Vahdat L, Pernas S, Schmid P, McArthur H et al. ( 2020 ) . Abstract OT1-08-06: International, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) . Cancer Research . vol. 80 ,
Schmid P, Cortes J, Robson M, Iwata H, Hegg R, Verma S, Nechaeva M, Xu B et al. ( 2020 ) . Abstract OT2-08-02: Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290) . Cancer Research . vol. 80 ,
Jhaveri K, Kalinsky K, Bedard P, Cervantes A, Saura C, Krop I, Hamilton E, Schmid P et al. ( 2020 ) . Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA -mutant HR+/HER2- breast cancer . Cancer Research . vol. 80 ,
Pérez-García JM, Llombart-Cussac A, Holgado E, Curigliano G, Miranda EL, Alonso-Romero JL, Bermejo B, Calvo L et al. ( 2020 ) . Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study) . Cancer Research . vol. 80 ,
Cameron D, Symeonides S, Brunt M, Schmid P, Waters S, Twelves C, Barrett-Lee P, Bartlett J et al. ( 2020 ) . Abstract P3-11-09: ARISTACAT - Ar omatase i nhibition plus minus s araca t inib as a dvanced breast ca ncer t herapy: A randomised phase II study of aromatase inhibition plus/minus the Src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer . Cancer Research . vol. 80 ,
Casadevall D, Mestres JA, Rojo F, Bellosillo B, González A, Serra V, Bellet M, Gil MA et al. ( 2020 ) . Abstract P4-10-17: Baseline and pharmacodynamic changes of circulating exosomal microRNAs predict early versus late progression to palbociclib plus endocrine therapy in patients with metastatic breast cancer. A sub-analysis of the PARSIFAL-1 trial . Cancer Research . vol. 80 ,
Robertson JF, Evans A, Henschen S, Kirwan C, Jahan A, Kenny L, Dixon JM, Schmid P et al. ( 2020 ) . Abstract P6-04-01: A pre-surgical, window of opportunity study comparing the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer . Cancer Research . vol. 80 ,
Rugo H, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Diéras V et al. ( 2020 ) . Abstract PD1-07: Exploratory analytical harmonization of PD-L1 immunohistochemistry assays in advanced triple-negative breast cancer: A retrospective substudy of IMpassion130 . Cancer Research . vol. 80 ,
Loi S, Winer E, Lipatov O, Im S-A, Goncalves A, Cortes J, Lee KS, Schmid P et al. ( 2020 ) . Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) . Cancer Research . vol. 80 ,
Reinisch M, Gluz O, Ataseven B, Schmid P, Blohmer J-U, Dittmer-Grabwoski C, Rueland A, Bruzas S et al. ( 2020 ) . Abstract PD5-09: Prognostic and predictive impact of genes and signatures measured with the BC360 panel (Nanostring) in node positive (≥pN2a) high risk patients (pts) receiving dose dense (dd) versus standard dosed chemotherapy in an adjuvant randomized trial with a long term follow-up (FU) . Cancer Research . vol. 80 ,
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH et al. ( 2020 ) . Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: The PAKT trial . Journal of Clinical Oncology vol. 38 , ( 5 ) 423 - 433 .
Schmid P ( 2020 ) . KEYNOTE-522 Study of Pembro plus Chemo vs. Placebo plus Chemo as Neoadjuvant Treatment Followed by Pembro vs. Placebo as Adjuvant Treatment for Early TNBC: Pathologic Complete Response in Key Subgroups . ANNALS OF SURGICAL ONCOLOGY . vol. 27 , S129 - S129 .
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V et al. ( 2020 ) . Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial . The Lancet Oncology vol. 21 , ( 1 ) 44 - 59 .
Cardoso F, Bardia A, André F, Cescon DW, McArthur H, Telli M, Loi S, Cortes J et al. ( 2019 ) . 24TiP KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2−breast cancer . Annals of Oncology vol. 30 , ix7 - ix8 .
Iwata H, Im S-A, Sohn J, Jung KH, Im Y-H, Lee KS, Inoue K, Tamura K et al. ( 2019 ) . 37O Subgroup analysis of IMpassion130: Atezolizumab + nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries . Annals of Oncology vol. 30 , ix13 - ix14 .
Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G et al. ( 2019 ) . Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women with Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial . JAMA Oncology vol. 5 , ( 11 ) 1556 - 1563 .
Cardoso F, Bardia A, Andre F, Cescon DW, McArthur H, Telli M, Loi S, Cortes J et al. ( 2019 ) . KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2-breast cancer . ANNALS OF ONCOLOGY . vol. 30 ,
Iwata H, Im S-A, Sohn J, Jung KH, Im Y-H, Lee KS, Inoue K, Tamura K et al. ( 2019 ) . Subgroup analysis of IMpassion130: Atezolizumab plus nab-paclitaxel (nab-P) in patients (pts) with advanced triple-negative breast cancer (TNBC) in Asian countries . ANNALS OF ONCOLOGY . vol. 30 ,
Schmid P, Rugo HS, Cortes J, Huang DC-L, Crossley K, Massey D, III BHA ( 2019 ) . XENERA (TM)-1: A phase II trial of xentuzumab (Xe) in combinationwith everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 15 , 158 - 158 .
Crown J, Sablin M-P, Cortes J, Bergh J, Im S-A, Lu Y-S, Martinez N, Neven P et al. ( 2019 ) . Xentuzumab (BI 836845), an IGF-neutralizing antibody, combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer: Randomised phase 2 results . ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY . vol. 15 , 173 - 173 .
Crown J, Sablin M-P, Cortes J, Bergh J, Im S-A, Lu Y-S, Martinez N, Neven P et al. ( 2019 ) . Xentuzumab (BI 836845), an IGF-neutralizing antibody, combined with exemestane and everolimus in hormone receptor-positive (HR plus ) locally advanced/metastatic breast cancer: Randomized Phase 2 Results . BRITISH JOURNAL OF CANCER . vol. 121 , 20 - 20 .
Cussac AL, Medioni J, Colleoni MA, Ettl J, Schmid P, Macpherson I, Gligorov J, Albanell J et al. ( 2019 ) . 387TiPPalbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial . Annals of Oncology vol. 30 , ( Supplement_5 )
Cortes J, Lipatov O, Im S-A, Goncalves A, Lee KS, Schmid P, Tamura K, Testa L et al. ( 2019 ) . KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) . ANNALS OF ONCOLOGY . vol. 30 , 859 - + .
Schmid P, Cortes J, Dent R, Pusztai L, McArthur HL, Kuemmel S, Bergh J, Denkert C et al. ( 2019 ) . KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) . ANNALS OF ONCOLOGY . vol. 30 , 853 - 854 .
Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Dieras VC et al. ( 2019 ) . LBA20 Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 . Annals of Oncology vol. 30 , v858 - v859 .
Cortés J, Lipatov O, Im S-A, Gonçalves A, Lee KS, Schmid P, Tamura K, Testa L et al. ( 2019 ) . LBA21 KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) . Annals of Oncology vol. 30 , v859 - v860 .
Schmid P, Cortés J, Dent R, Pusztai L, McArthur HL, Kuemmel S, Bergh J, Denkert C et al. ( 2019 ) . LBA8_PR KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) . Annals of Oncology vol. 30 , v853 - v854 .
Llombart Cussac A, Medioni J, Colleoni MA, Ettl J, Schmid P, Macpherson I, Gligorov J, Albanell J et al. ( 2019 ) . Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial . ANNALS OF ONCOLOGY . vol. 30 ,
Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Dieras VC et al. ( 2019 ) . Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130 . ANNALS OF ONCOLOGY . vol. 30 , 858 - + .
Schmid P, Loirat D, Savas P, Espinosa E, Boni V, Italiano A, White S, Singel SM et al. ( 2019 ) . Abstract CT049: Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC) . Cancer Research . vol. 79 , ct049 - ct049 .
Loi S, Schmid P, Cortés J, Cescon DW, Winer EP, Toppmeyer D, Rugo HS, Laurentiis MD et al. ( 2019 ) . Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 . Cancer Research . vol. 79 ,
von Moos R, Emens LA, Loi S, Rugo HS, Schneeweiss A, Dieras V, Iwata H, Barrios CH et al. ( 2019 ) . IMpassion130: Efficacy in immune biomarker subgroups of atezolizumab plus nab-paclitaxel in patients with triple-negative BC . SWISS MEDICAL WEEKLY . vol. 149 , 13S - 14S .
Cortés J, André F, Gonçalves A, Kümmel S, Martín M, Schmid P, Schuetz F, Swain SM et al. ( 2019 ) . IMpassion132 Phase III trial: Atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer . Future Oncology vol. 15 , ( 17 ) 1951 - 1961 .
Schneeweiss A, Rugo HS, Winer EP, Barrios CH, Iwata H, Dieras V, Loi S, Maiya V et al. ( 2019 ) . IMpassion130: Expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in patients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC) . Journal of Clinical Oncology . vol. 37 , 1068 - 1068 .
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Henschel V et al. ( 2019 ) . IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab- paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC) . Journal of Clinical Oncology . vol. 37 , 1003 - 1003 .
Cardoso F, Bardia A, Andre F, Cescon DW, McArthur HL, Telli ML, Loi S, Cortes J et al. ( 2019 ) . KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer . Journal of Clinical Oncology . vol. 37 , tps601 - tps601 .
Adams S, Dieras V, Barrios CH, Winer EP, Schneeweiss A, Iwata H, Loi S, Patel S et al. ( 2019 ) . Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nabpaclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC) . Journal of Clinical Oncology . vol. 37 , 1067 - 1067 .
Schmid P, Rugo HS, Cortes J, Huang C-L, Crossley K, Massey D, Burris HA ( 2019 ) . XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement . Journal of Clinical Oncology . vol. 37 , tps1103 - tps1103 .
Loi S, Schmid P, Aktan G, Karantza V, Salgado R ( 2019 ) . 4ORelationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro)+chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial . Annals of Oncology vol. 30 , ( Supplement_3 )
Winters Z, Roberts N, McCartan N, Potyka I, Brunt M, Maxwell A, Greenwood R, Ingram J et al. ( 2019 ) . 16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654) . European Journal of Surgical Oncology vol. 45 , ( 5 )
Winters Z, Roberts N, Brunt M, Greenwood R, Maxwell A, Potyka I, Ingram J, Kandiyali R et al. ( 2019 ) . Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK . ANNALS OF SURGICAL ONCOLOGY . vol. 26 , 58 - 60 .
Loi S, Schmid P, Aktan G, Karantza V, Salgado R ( 2019 ) . Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (pembro) plus chemotherapy (CT) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): Phase Ib KEYNOTE-173 trial . ANNALS OF ONCOLOGY . vol. 30 ,
Rosenthal R, Cadieux EL, Salgado R, Al-Bakir M, Moore DA, Hiley CT, Lund T, Tanić M et al. ( 2019 ) . Neoantigen-directed immune escape in lung cancer evolution . Nature vol. 567 , ( 7749 ) 479 - 485 .
Schmid P, Chui SY, Emens LA ( 2019 ) . Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply . The New England journal of medicine vol. 380 , ( 10 ) 987 - 988 .
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H et al. ( 2019 ) . Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study . Annals of Oncology vol. 30 , ( 3 ) 397 - 404 .
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H et al. ( 2019 ) . Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study . Annals of Oncology vol. 30 , ( 3 ) 405 - 411 .
Emens L, Loi S, Rugo H, Schneeweiss A, Diéras V, Iwata H, Barrios C, Nechaeva M et al. ( 2019 ) . Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab -paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer . Cancer Research . vol. 79 ,
Yardley D, Abu-Khalaf M, Boni V, Brufsky A, Emens L, Gutierrez M, Hurvitz S, Im S-A et al. ( 2019 ) . Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer . Cancer Research . vol. 79 ,
Schmid P, Nunes A, Lall R, D'Cruz C, Grinsted L, Lanasa M ( 2019 ) . Abstract OT3-01-01: BEGONIA: Phase Ib/II open-label, platform study of safety and efficacy of durvalumab, paclitaxel and other novel oncology therapy agents as first-line (1L) therapy in patients with metastatic triple negative breast cancer (mTNBC) . Cancer Research . vol. 79 ,
Cardoso F, Bardia A, Andre F, Cescon D, McArthur H, Telli M, Loi S, Cortés J et al. ( 2019 ) . Abstract OT3-04-03: KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk early-stage ER+/HER2– breast cancer . Cancer Research . vol. 79 ,
Schmid P, Pinder S, Wheatley D, Zummit C, Macaskill E, Hu J, Price R, Bundred N et al. ( 2019 ) . Abstract P2-08-02: Interaction of PIK3CA mutation subclasses with response to preoperative treatment with the PI3K inhibitor pictilisib in patients with estrogen receptor-positive breast cancer . Cancer Research . vol. 79 ,
Loi S, Schmid P, Cortés J, Park Y, Muñoz-Couselo E, Kim S-B, Sohn J, Im S-A et al. ( 2019 ) . Abstract P3-10-09: Relationship between tumor infiltrating lymphocytes (TILs) and response to pembrolizumab (Pembro)+chemotherapy (Chemo) as neoadjuvant treatment (NAT) for triple-negative breast cancer (TNBC): phase Ib KEYNOTE-173 trial . Cancer Research . vol. 79 ,
Vahdat L, Forero-Torres A, Schmid P, Blackwell K, Telli M, Melisko M, Holgado E, Moebus V et al. ( 2019 ) . Abstract P6-20-01: METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC) . Cancer Research . vol. 79 ,
Crown J, Sablin M-P, Cortés J, Bergh J, Im S-A, Lu Y-S, Martínez N, Neven P et al. ( 2019 ) . Abstract P6-21-01: Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results . Cancer Research . vol. 79 ,
Schmid P, Park Y, Muñoz-Couselo E, Kim S-B, Sohn J, Im S-A, Holgado E, Foukakis T et al. ( 2019 ) . Abstract PD5-01: KEYNOTE-173: Phase 1b multicohort study of pembrolizumab (Pembro) in combination with chemotherapy as neoadjuvant treatment for triple-negative breast cancer (TNBC) . Cancer Research . vol. 79 ,
Emens LA, Cruz C, Eder JP, Braiteh F, Chung C, Tolaney SM, Kuter I, Nanda R et al. ( 2019 ) . Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients with Metastatic Triple-Negative Breast Cancer: A Phase 1 Study . JAMA Oncology vol. 5 , ( 1 ) 74 - 82 .
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R et al. ( 2018 ) . Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer . New England Journal of Medicine vol. 379 , ( 22 ) 2108 - 2121 .
Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ et al. ( 2018 ) . FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC . Journal of Thoracic Oncology vol. 13 , ( 11 ) 1733 - 1742 .
Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE, Wistuba I et al. ( 2018 ) . Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1) . Proceedings of the National Academy of Sciences of the United States of America vol. 115 , ( 43 ) E10119 - E10126 .
Schmid P ( 2018 ) . ESMO 2018 presidential symposium - IMpassion130: Atezolizumab+nab-paclitaxel in triple-negative breast cancer . ESMO Open vol. 3 , ( 6 )
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Hegg R et al. ( 2018 ) . IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC) . Annals of oncology : official journal of the European Society for Medical Oncology vol. 29 , viii707 - viii708 .
Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R et al. ( 2018 ) . MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC . Journal of Thoracic Oncology . vol. 13 ,
Chau I, Haag GM, Rahma OE, Macarulla TM, McCune SL, Yardley DA, Solomon BJ, Johnson M et al. ( 2018 ) . MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types . Annals of oncology : official journal of the European Society for Medical Oncology . vol. 29 , viii439 - viii440 .
Winters ZE, Horsnell J, Elvers KT, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR et al. ( 2018 ) . Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers . BJS Open vol. 2 , ( 4 ) 162 - 174 .
García JMP, Llombart A, Alonso JL, Bermejo B, Calvo L, Carañana V, Curigliano G, Sánchez SDLC et al. ( 2018 ) . Abstract CT152: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study) . Cancer Research . vol. 78 , ct152 - ct152 .
Winters Z, Horsnell J, Elvers K, Maxwell AJ, Jones LJ, Shaaban AM, Schmid P, Williams NR et al. ( 2018 ) . A systematic review of the impact of breast conserving surgery on cancer outcomes of multiple ipsilateral breast cancers (MIBC)–the case for a randomised trial . European Journal of Surgical Oncology vol. 44 , ( 6 )
Schmid P, Abraham J, Chan S, Wheatley D, Brunt M, Nemsadze G, Baird R, Park YH et al. ( 2018 ) . AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial . Journal of Clinical Oncology . vol. 36 , 1007 - 1007 .
Dent R, Andre F, Goncalves A, Kummel S, Martin M, Schmid P, Schuetz F, Swain SM et al. ( 2018 ) . IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC) . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) tps1115 - tps1115 .
Schmid P, Cortes J, Bergh JCS, Pusztai L, Denkert C, Verma S, McArthur HL, Kummel S et al. ( 2018 ) . KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC) . Journal of Clinical Oncology . vol. 36 , tps602 - tps602 .
Schmid P, Cortes J, Bergh JCS, Pusztai L, Denkert C, Verma S, McArthur HL, Kummel S et al. ( 2018 ) . KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 36 ,
Kim D-W, Gadgeel SM, Gettinger SN, Riely GJ, Oxnard GR, Mekhail T, Schmid P, Dowlati A et al. ( 2018 ) . Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK + advanced NSCLC (aNSCLC) . Journal of Clinical Oncology . vol. 36 , 9009 - 9009 .
Winter H, Rumbles S, Hughes B, O'Brien M, Rahman S, Murias C, Conibear J, Harries M et al. ( 2018 ) . Virtual metastatic breast multidisciplinary meeting: The next step in personalised medicine . Journal of Clinical Oncology vol. 36 , ( 15_suppl ) e18794 - e18794 .
Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A et al. ( 2018 ) . Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe . HIV Medicine vol. 19 , ( 5 ) 324 - 338 .
Schmid PJ, Garciá-Gutierrez A, Jiménez J ( 2018 ) . Description and detection of burst events in turbulent flows . Journal of Physics: Conference Series . vol. 1001 ,
Vargas FA, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH et al. ( 2018 ) . Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies . Cancer Cell vol. 33 , ( 4 ) 649 - 663.e4 .
Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A et al. ( 2018 ) . Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort . HIV Medicine vol. 19 , ( 4 ) 252 - 260 .
Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE et al. ( 2018 ) . Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study . The Lancet Oncology vol. 19 , ( 4 ) 521 - 536 .
Fearon AE, Carter EP, Clayton NS, Wilkes EH, Baker AM, Kapitonova E, Bakhouche BA, Tanner Y et al. ( 2018 ) . PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer . Cell Reports vol. 22 , ( 9 ) 2469 - 2481 .
Schmid P, Zaiss M, Harper-Wynne C, Ferreira M, Dubey S, Chan S, Makris A, Nemsadze G et al. ( 2018 ) . Abstract GS2-07: MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer . Cancer Research . vol. 78 ,
Buchecker T, Schmid P, Renaudineau S, Diat O, Proust A, Pfitzner A, Bauduin P ( 2018 ) . Polyoxometalates in the Hofmeister series . Chem Commun (Camb) vol. 54 , ( 15 ) 1833 - 1836 .
Llombart-Cussac A, Curigliano G, Gebhart G, Gligorov J, Khaldoun K, Marme F, Prat A, Schmid P et al. ( 2018 ) . Chemotherapy-free trastuzumab and pertuzumab in HER2 [+] breast cancer: FDG-PET response-adapted strategy. The PHERGain study . CANCER RESEARCH . vol. 78 ,
Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H et al. ( 2018 ) . Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens . HIV Medicine vol. 19 , ( 2 ) 102 - 117 .
Adams S, Loi S, Toppmeyer DL, Cescon DW, De laurentiis M, Nanda R, Winer EP, Mukai H et al. ( 2018 ) . KEYNOTE-086 cohort B: Pembrolizumab monotherapy for PD-L1-positive, previously untreated, metastatic triple-negative breast cancer (mTNBC) . CANCER RESEARCH . vol. 78 ,
Molinero L, Chang C-W, Udyavar A, Fasso M, O'Hear C, Emens L, Cruz C, Hegde P et al. ( 2018 ) . Molecular characterization of tumors from metastatic TNBC patients treated with atezolizumab (atezo) . CANCER RESEARCH . vol. 78 ,
Verrill M, Wardley A, Retzler J, Smith AB, McNicol D, Dando S, Tran I, Leslie I et al. ( 2018 ) . Quality of life and ability to work in patients at different disease stages of HER2+breast cancer . CANCER RESEARCH . vol. 78 ,
Nathan MR, Schmid P ( 2018 ) . The emerging world of breast cancer immunotherapy . Breast vol. 37 , 200 - 206 .
Shepherd L, Borges H, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M et al. ( 2018 ) . The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people . HIV Medicine vol. 19 , ( 2 ) 90 - 101 .
Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O'Shaughnessy J, Gradishar W, Schmid P et al. ( 2018 ) . Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer . Journal of Clinical Oncology vol. 36 , ( 9 ) 884 - 890 .
Asselain B, Barlow W, Bartlett J, Bergh J, Bergsten-Nordström E, Bliss J, Boccardo F, Boddington C et al. ( 2018 ) . Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials . The Lancet Oncology vol. 19 , ( 1 ) 27 - 39 .
O'Leary K, Shia A, Schmid P ( 2017 ) . Epigenetic Regulation of EMT in Non-Small Cell Lung Cancer . Curr Cancer Drug Targets vol. 18 , ( 1 ) 89 - 96 .
Cortés J, Im SA, Holgado E, Perez-Garcia JM, Schmid P, Chavez-MacGregor M ( 2017 ) . The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies . Cancer Treatment Reviews vol. 61 , 53 - 60 .
McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S et al. ( 2017 ) . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution . Cell vol. 171 , ( 6 ) 1259 - 1271.e11 .
Hentrich M, Schipek-Voigt K, Jäger H, Schulz S, Schmid P, Stötzer O, Bojko P ( 2017 ) . Nivolumab in HIV-related non-small-cell lung cancer . Annals of Oncology vol. 28 , ( 11 )
Verrill M, Schmid P, Retzler J, Smith, Bottomley C, Dando S, Tran I, Leslie I et al. ( 2017 ) . PCN234 Work Productivity in HER2 Positive Breast Cancer: A Comparison of Patients Across Stages of Early and Metastatic Disease . Value in Health vol. 20 , ( 9 )
Bermingham S, Schmid P, Forster F, Cornic L, Theti D, Smith A ( 2017 ) . PCN86 Societal Costs of Er+/Her2- Advanced or Metastatic Breast Cancer in Post-Menopausal Women in The United Kingdom . Value in Health vol. 20 , ( 9 )
De Laurentiis M, Montemurro F, Bachelot T, Martin M, Barrios C, Kaufman B, Schmid P, Alba E et al. ( 2017 ) . The role of ribociclib in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer: the EarLEE adjuvant clinical trials program . Annals of oncology : official journal of the European Society for Medical Oncology vol. 28 ,
Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP et al. ( 2017 ) . Effects of anacetrapib in patients with atherosclerotic vascular disease . New England Journal of Medicine vol. 377 , ( 13 ) 1217 - 1227 .
Schmid P, Castan JC, Bergh J, Pusztai L, Denkert C, Verma S, McArthur HL, Zhao J et al. ( 2017 ) . 233TiP KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC) . Annals of Oncology vol. 28 ,
Jimenez MM, Bachelot T, Barrios C, Blackwell K, Chia S, De Laurentiis M, Hurvitz S, Janni W et al. ( 2017 ) . 323TiP EarLEE-1: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), high-risk, early breast cancer (EBC) . Annals of Oncology vol. 28 ,
Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. ( 2017 ) . A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers . ANNALS OF ONCOLOGY . Conference: ESMO vol. 28 ,
Schulz C, Schmid P, Hedge P, Zou W, Kowanetz M, Mariathasan S, Gadgeel S, Powles T et al. ( 2017 ) . Association of PD-L2 expression in human tumors with atezolizumab activity . ONCOLOGY RESEARCH AND TREATMENT . vol. 40 , 134 - 134 .
Martin Jimenez M, Bachelot T, Barrios C, Blackwell K, Chia S, De Laurentiis M, Hurvitz S, Janni W et al. ( 2017 ) . EarLEE-1: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-), high-risk, early breast cancer (EBC) . ANNALS OF ONCOLOGY . vol. 28 ,
Loi S, Adams S, Schmid P, Cortés J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS et al. ( 2017 ) . LBA13 Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 . Annals of Oncology vol. 28 ,
Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al. ( 2017 ) . LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers . Annals of Oncology vol. 28 ,
Loi S, Adams S, Schmid P, Cortes J, Cescon DW, Winer EP, Toppmeyer DL, Rugo HS et al. ( 2017 ) . Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 . ANNALS OF ONCOLOGY . vol. 28 ,
Chupin J, Nagano A, Haley V, Lenihan C, Cavicchioli F, O’Leary K, Sahgal N, Nigro CL et al. ( 2017 ) . Abstract 104: miRNAs in the 14q32 cluster are involved in lapatinib resistance . Cancer Research . vol. 77 , 104 - 104 .
Beddowes E, Spicer J, Chan PY, Khadeir R, Garcia Corbacho J, Repana D, Steele JP, Schmid P et al. ( 2017 ) . Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1–deficient thoracic cancers . Journal of Clinical Oncology vol. 35 , ( 16 ) 1778 - 1785 .
Schmid P, Forster MD, Summers YJ, Good J, Sarker S-J, Lim L, Mousa K, Middleton GW ( 2017 ) . A study of vistusertib in combination with selumetinib in patients with advanced cancers: TORCMEK phase Ib results . JOURNAL OF CLINICAL ONCOLOGY . Conference: ESMO vol. 35 ,
Hiley CT, Ahmad T, Jamal-Hanjani M, Abbosh C, Ngai Y, Hackshaw A, Patterson P, Baijal S et al. ( 2017 ) . Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II) . Journal of Clinical Oncology . vol. 35 , tps9099 - tps9099 .
Traina TA, Yardley DA, Schwartzberg LS, O'Shaughnessy J, Cortes J, Awada A, Kelly CM, Trudeau ME et al. ( 2017 ) . Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 1089 - 1089 .
Schmid P, Park YH, Muñoz-Couselo E, Kim S-B, Sohn J, Im S-A, Holgado E, Wang Y et al. ( 2017 ) . Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173 . Journal of Clinical Oncology . vol. 35 , 556 - 556 .
Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H et al. ( 2017 ) . Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A . Journal of Clinical Oncology . vol. 35 , 1008 - 1008 .
Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H et al. ( 2017 ) . Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B . Journal of Clinical Oncology vol. 35 , ( 15_suppl ) 1088 - 1088 .
Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P et al. ( 2017 ) . Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort . Clinical Infectious Diseases vol. 64 , ( 10 ) 1413 - 1421 .
Seckl MJ, Ottensmeier CH, Cullen M, Schmid P, Ngai Y, Muthukumar D, Thompson J, Harden S et al. ( 2017 ) . Multicenter, phase III, randomized, double-blind, placebo-controlled trial of pravastatin added to first-line standard chemotherapy in small-cell lung cancer (LUNGSTAR) . Journal of Clinical Oncology vol. 35 , ( 14 ) 1506 - 1514 .
Oke A, Knox J, Tan J, Aigret B, Schmid P, Coleman RE, Cuzick J, Thorat MA ( 2017 ) . Barriers to recruitment from primary care into a trial in secondary care settings: experience from the feasibility study of IBIS-3 trial . TRIALS . Conference: ICTMC/SCT 2017 vol. 18 ,
Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA et al. ( 2017 ) . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution . Nature vol. 545 , ( 7655 ) 446 - 451 .
Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R et al. ( 2017 ) . Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors . Immunity vol. 46 , ( 4 ) 577 - 586 .
López-Miranda E, Gávila J, Pernas S, Saura C, Oliveira M, Serra V, Schmid P, Lord S et al. ( 2017 ) . Abstract OT1-01-06: PIQHASSO: Open label, non-randomized, multicenter phase 1/2b study investigating safety and efficacy of PQR309 and eribulin combination in patients (pts) with locally advanced (LA) or metastatic HER2 (-) and triple-negative breast cancer (TNBC) (study PQR309-007) . Cancer Research . vol. 77 ,
Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, Chupin J, Shia A, Schmid P ( 2017 ) . Abstract P3-03-12: CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy . Cancer Research . vol. 77 ,
Schmid P, Pinder SE, Purushotham A, Thompson AM ( 2017 ) . Reply to R.F. Sweis et al . Journal of Clinical Oncology vol. 35 , ( 2 ) 261 - 262 .
Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al. ( 2017 ) . Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial . JAMA oncology vol. 3 , ( 1 ) 58 - 66 .
Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S et al. ( 2017 ) . Arginine deprivation with pegylated arginine deiminase in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma a randomized clinical trial . JAMA Oncology vol. 3 , ( 1 ) E1 - E9 .
Possinger K, Regierer A, Eucker J, Dieing A, Eucker J, Flath B, Folprecht G, Geißler M et al. ( 2017 ) . Herausgeber- und Autorenverzeichnis . Facharztwissen Hämatologie Onkologie ,
Mok T, Schmid P, De Castro G, Syrigos K, Martin C, Yamamoto N, Arén O, Arrieta O et al. ( 2017 ) . P2.06-022 First-Line Durvalumab plus Tremelimumab vs Platinum-Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study Topic: Phase III . Journal of Thoracic Oncology . vol. 12 ,
Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R et al. ( 2017 ) . P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC Topic: IT . Journal of Thoracic Oncology . vol. 12 , s1302 - s1303 .
Bermingham S, Schmid P, Forster F, Comic L, Theti D, Smith A ( 2017 ) . SOCIETAL COSTS OF ER+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN POST-MENOPAUSAL WOMEN IN THE UNITED KINGDOM . VALUE IN HEALTH . vol. 20 , A427 - A427 .
Verrill M, Schmid P, Retzler J, Smith AB, Bottomley CJ, Dando S, Tran I, Leslie I et al. ( 2017 ) . WORK PRODUCTIVITY IN HER2 POSITIVE BREAST CANCER: A COMPARISON OF PATIENTS ACROSS STAGES OF EARLY AND METASTATIC DISEASE . VALUE IN HEALTH . vol. 20 , A454 - A454 .
Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V et al. ( 2016 ) . 136TiP IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC . Annals of Oncology vol. 27 ,
Mok T, Schmid P, de Castro G, Syrigos K, Martin C, Yamamoto N, Arén O, Arrieta O et al. ( 2016 ) . 482TiP Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE . Annals of Oncology vol. 27 ,
Jehn CF, Hemmati P, Lehenbauer-Dehm S, Kümmel S, Flath B, Schmid P ( 2016 ) . Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study . Clinical Breast Cancer vol. 16 , ( 6 ) 514 - 519 .
Mok T, Schmid P, Jr DCG, Syrigos K, Martin C, Yamamoto N, Aren O, Arrieta O et al. ( 2016 ) . Global, Phase 3 study of first-line durvalumab (MEDI4736) + tremelimumab vs standard of care platinum-based chemotherapy in advanced/metastatic NSCLC: NEPTUNE . ANNALS OF ONCOLOGY . vol. 27 ,
Emens L, Adams S, Loi S, Schneeweiss A, Rugo H, Winer E, Barrios C, Dieras V et al. ( 2016 ) . IMpassion130: Phase III trial comparing 1L atezolizumab with nab-paclitaxel versus placebo with nab-paclitaxel in treatment-naive patients with mTNBC . ANNALS OF ONCOLOGY . vol. 27 ,
Ma BBY, Rudin CM, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor VM et al. ( 2016 ) . Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC . ANNALS OF ONCOLOGY . vol. 27 ,
Schmid-Araya JM, Schmid PE, Tod SP, Esteban GF ( 2016 ) . Trophic positioning of meiofauna revealed by stable isotopes and food web analyses . Ecology vol. 97 , ( 11 ) 3099 - 3109 .
Schmid P, Melisko M, Yardley DA, Blackwell K, Forero A, Ouellette G, He Y, Bagley RG et al. ( 2016 ) . METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC) . Annals of Oncology . vol. 27 ,
Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H, Aimi J, Derynck MK et al. ( 2016 ) . Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant . Nature Communications vol. 7 , ( 1 )
Lenihan C, Cavicchioli F, O’Leary K, Shia A, Schmid P ( 2016 ) . Abstract 2110: The role of VAV-interacting Kruppel-like factor (VIK) in resistance to palbociclib in estrogen receptor-positive breast cancer . Cancer Research . vol. 76 , 2110 - 2110 .
Bouchekioua-Bouzaghou K, Lenihan C, Shia A, Wilkes E, Casado-Izquierdo P, Cutillas P, Schmid P ( 2016 ) . Abstract 2819: Characterization of the mechanisms of early and later stages of resistance to the selective CDK4/6 inhibitor palbociclib . Cancer Research . vol. 76 , 2819 - 2819 .
Komulainen E, Shia A, Bansal J, Cavicchioli F, O’Leary K, Foster J, Schmid P ( 2016 ) . Abstract 3759: Inhibition of heat shock protein 27 (Hsp27) expression by apatorsen as a therapeutic strategy in breast cancer . Cancer Research . vol. 76 , 3759 - 3759 .
Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N et al. ( 2016 ) . Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer . Journal of Clinical Oncology vol. 34 , ( 17 ) 1987 - 1994 .
Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B et al. ( 2016 ) . Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial . The Lancet Oncology vol. 17 , ( 6 ) 811 - 821 .
Schmid P, Wheatley DA, Thompson AM, Roy P, Bundred NJ, Purushotham AD, McIntosh S, Kummel S et al. ( 2016 ) . ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer . JOURNAL OF CLINICAL ONCOLOGY . Conference: ASCO vol. 34 ,
Schmid P, Hegde PS, Zou W, Kowanetz M, Mariathasan S, Molinero L, Gadgeel SM, Powles T et al. ( 2016 ) . Association of PD-L2 expression in human tumors with atezolizumab activity . Journal of Clinical Oncology . vol. 34 , 11506 - 11506 .
Cortes J, Martinez Janez N, Sablin M-P, Perez-Fidalgo JA, Neven P, Hedayati E, Ballester A, Ehrhart M-P et al. ( 2016 ) . Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results . Journal of Clinical Oncology . vol. 34 , 530 - 530 .
Mok T, Schmid P, Arén O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva K et al. ( 2016 ) . 192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC . Journal of Thoracic Oncology vol. 11 , ( 4 ) S140 - S141 .
Cortes J, Martinez Janesz N, Sablin MP, Perez-Fidalgo JA, Neven P, Hedayati E, Ballester A, Ehrhart MP et al. ( 2016 ) . Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralising antibody, in combination with exemestane and everolimus in postmenopausal women with hormone receptor-positive, locally advanced or metastatic breast cancer: Preliminary results of the Phase 1b part . EUROPEAN JOURNAL OF CANCER . vol. 57 , S112 - S112 .
Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L et al. ( 2016 ) . Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)? . Breast vol. 26 , 149 - 150 .
Emens L, Adams S, Loi S, Schmid P, Schneeweiss A, Rugo H, Chui S, Winer E ( 2016 ) . Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) . Cancer Research . vol. 76 ,
Schmid P, Ferreira M, Dubey S, Zaiss M, Harper-Wynne C, Makris A, Brown V, Kristeleit H et al. ( 2016 ) . Abstract OT1-03-12: MANTA: A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer . Cancer Research . vol. 76 ,
Schmid P, Wheatley D, Baird R, Chan S, Abraham J, Tutt A, Kristeleit H, Patel G et al. ( 2016 ) . Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603) . Cancer Research . vol. 76 ,
Lenihan C, Bouchekioua-Bouzaghou K, Shia A, Wilkes E, Casado-Izquierdo1 P, Cutillas P, Schmid P ( 2016 ) . Abstract P3-06-02: Characterization of resistance to the selective CDK4/6 inhibitor palbociclib in ER positive breast cancer . Cancer Research . vol. 76 ,
Hampsch R, Shee K, Miller T ( 2016 ) . Abstract P5-03-01: Therapeutic targeting of Rac GTPases in ER+ and HER2+ breast cancer . Cancer Research . vol. 76 ,
Schmid P, Pinder S, Bundred N, Wheatley D, Macaskill J, Zammit C, Hu J, Price R et al. ( 2016 ) . Abstract P5-13-01: Transcript analysis of PI3K and immune-related genes and gene signatures in the pre- and post-treatment samples from the window of opportunity study of anastrozole and anastrozole with pictilisib (GDC-0941) in patients with HR-positive early breast cancer (OPPORTUNE study) . Cancer Research . vol. 76 ,
Spoerke J, Gendreau S, Johnston S, Schmid P, Krop I, Qui J, Derynck M, Chan I et al. ( 2016 ) . Abstract PD6-03: High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI) . Cancer Research . vol. 76 ,
Spoerke J, Gendreau S, Johnston S, Schmid P, Krop I, Qui J, Derynck M, Chan I et al. ( 2016 ) . High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized phase II study testing pictilisib (GDC-0941) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor (AI) . CANCER RESEARCH . vol. 76 ,
Kovari H, Sabin CA, Ledergerber B, Ryom L, Reiss P, Law M, Pradier C, Dabis F et al. ( 2016 ) . Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study . Open Forum Infect Dis vol. 3 , ( 1 )
Mok T, Schmid P, Arén O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva C et al. ( 2015 ) . 480TiPPhase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE . Annals of Oncology vol. 26 , ( suppl_9 ) ix147 - ix147 .
Pacey S, Spicer JF, Chan PY, Hategan M, Repana D, Steele JP, Schmid P, Cook GJR et al. ( 2015 ) . Abstract B23: A phase 1 study in patients with mesothelioma or non small cell lung tumours requiring arginine to assess ADI-PEG 20 with pemetrexed and cisplatin (TRAP study) . Molecular Cancer Therapeutics . vol. 14 , b23 - b23 .
Mok T, Schmid P, Aren O, Arrieta O, Gottfried M, Jazieh AR, Ramlau R, Timcheva C et al. ( 2015 ) . Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE . ANNALS OF ONCOLOGY . vol. 26 , 147 - 147 .
Jehn CF, Becker B, Flath B, Nogai H, Vuong L, Schmid P, Lüftner D ( 2015 ) . Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression . Journal of Neuroimmunology vol. 287 , 88 - 92 .
O'Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K et al. ( 2015 ) . Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer . British Journal of Cancer vol. 113 , ( 6 ) 970 - 978 .
Schmid P, Kowanetz M, Koeppen H, Zou W, Wistuba I, Kockx M, Kadel EE, Chaft J et al. ( 2015 ) . 3017 NSCLC with high PD-L1 expression on tumor cells or tumorinfiltrating immune cells represents distinct cancer subtypes . European Journal of Cancer . vol. 51 ,
Schmid P, Muthukumar D, Blackhall F, Lester J, Khan S, Illsley MC, Adams J, Baijal S et al. ( 2015 ) . Addition of Hsp27 Inhibitor Apatorsen to First-Line Gemcitabine/Carboplatin in Advanced Squamous Cell Lung Cancer: Design of the Cedar (TM) Trial . JOURNAL OF THORACIC ONCOLOGY vol. 10 , ( 9 ) S664 - S664 .
O Leary K, Shia A, Cavicchioli F, Haley V, Comino A, Merlano M, Mauri F, Walter K et al. ( 2015 ) . Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer . British Journal of Cancer
Diéras V, Campone M, Yardley DA, Romieu G, Valero V, Isakoff SJ, Koeppen H, Wilson TR et al. ( 2015 ) . Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer . Annals of Oncology vol. 26 , ( 9 ) 1904 - 1910 .
Schmid P, Muthukumar D, Blackhall FH, Lester JF, Khan S, Illsley M, Adams J, Garcia-Alonso A et al. ( 2015 ) . Addition of apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar study . Journal of Clinical Oncology vol. 33 , ( 15_suppl ) tps8111 - tps8111 .
Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C et al. ( 2015 ) . Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) . JOURNAL OF CLINICAL ONCOLOGY . vol. 33 ,
Spigel DR, Chaft JE, Gettinger SN, Chao BH, Dirix LY, Schmid P, Chow LQM, Chappey C et al. ( 2015 ) . Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC) . Journal of Clinical Oncology vol. 33 , ( 15_suppl ) 8028 - 8028 .
Szlosarek PW, Spicer JF, Szyszko T, Cook GJR, Chan PY, Hategan M, Repana D, Steele JP et al. ( 2015 ) . Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer . Journal of Clinical Oncology . vol. 33 , tps2612 - tps2612 .
Cortes Castan J, Schmid P, Awada A, Uppal H, Tudor IC, Blaney ME, Steinberg JL, Yardley DA et al. ( 2015 ) . Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR plus triple-negative breast cancer (TNBC) . ANNALS OF ONCOLOGY . vol. 26 ,
Cortes Castan J, Schmid P, Awada A, Uppal H, Tudor IC, Blaney ME, Steinberg JL, Yardley DA et al. ( 2015 ) . Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC) . Annals of Oncology vol. 26 ,
Krop I, Johnston S, Mayer IA, Dickler M, Ganju V, Forero-Torres A, Melichar B, Morales S et al. ( 2015 ) . Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results . Conference: General Session Abstracts
Schmid P, Pinder SE, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Bundred N et al. ( 2015 ) . Abstract S2-03: Preoperative window of opportunity study of the PI3K inhibitor pictilisib (GDC-0941) plus anastrozole vs anastrozole alone in patients with ER+, HER2-negative operable breast cancer (OPPORTUNE study) . Conference: General Session Abstracts
Zhang M, Martinelli F, Wu J, Schmid PJ, Quadrio M ( 2015 ) . Modal and non-modal stability analysis of electrohydrodynamic flow with and without cross-flow . Journal of Fluid Mechanics vol. 770 , 319 - 349 .
Possinger K, Regierer AC, Dieing A, Engelhardt D, Eucker J, Flath B, Folprecht G, Geißler M et al. ( 2015 ) . Herausgeber- und Autorenverzeichnis . Facharzt Hämatologie Onkologie ,
Neumayr G, Fries D, Mittermayer M, Humpeler E, Klingler A, Schobersberger W, Spiesberger R, Pokan R et al. ( 2014 ) . Effects of hiking at moderate and low altitude on cardiovascular parameters in male patients with metabolic syndrome: Austrian Moderate Altitude Study . Wilderness &amp; environmental medicine vol. 25 , ( 3 ) 329 - 334 .
Meisenberg C, Ward SE, Schmid P, El-Khamisy SF ( 2014 ) . TDP1/TOP1 Ratio as a Promising Indicator for the Response of Small Cell Lung Cancer to Topotecan . J Cancer Sci Ther vol. 6 , ( 7 ) 258 - 267 .
Cope S, Zhang J, Saletan S, Smiechowski B, Jansen JP, Schmid P ( 2014 ) . A process for assessing the feasibility of a network meta-analysis: A case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer . BMC Medicine vol. 12 , ( 1 )
Dizdarevic S, McCready R, Turner JFC, Bagley MC, Blower P, Schmid P, Flux G, Hall A et al. ( 2014 ) . Radiolabelled apoptotic probe may be a vehicle for a novel multimodality radionuclide tumour therapy . EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING vol. 41 , ( 6 ) 1255 - 1256 .
Traina TA, O'Shaughnessy J, Kelly CM, Schwartzberg LS, Gucalp A, Peterson AC, Tudor IC, Blaney ME et al. ( 2014 ) . A phase 2 single-arm study of the clinical activity and safety of enzalutamide in patients with advanced androgen receptor-positive triple-negative breast cancer . Journal of Clinical Oncology . vol. 32 , tps1144 - tps1144 .
Britton D, Zen Y, Quaglia A, Selzer S, Mitra V, Löbner C, Jung S, Böhm G et al. ( 2014 ) . Quantification of pancreatic cancer proteome and phosphorylome: Indicates molecular events likely contributing to cancer and activity of drug targets . PLoS ONE vol. 9 , ( 3 )
Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, Mulatero C, Miller N et al. ( 2014 ) . A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer . ANNALS OF ONCOLOGY vol. 25 , ( 2 ) 505 - 511 .
Wonisch M, Berent R, Klicpera M, Laimer H, Marko C, Pokan R, Schmid P, Schwann H ( 2014 ) . Practice guidelines for exercise testing . Atemwegs- und Lungenkrankheiten vol. 40 , ( 6 ) 223 - 244 .
Denne L, Shia A, Komulainen E, Haley V, Lenihan C, Cavicchioli F, O'Leary K, Schmid P ( 2013 ) . Abstract P2-09-05: The potent anti-androgen enzalutamide demonstrates broad anti-tumour activity across all androgen receptor-positive triple-negative breast cancer subtypes . Cancer Research vol. 73 , ( 24_Supplement )
Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K et al. ( 2013 ) . Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer . Breast Cancer Research vol. 15 , ( 5 )
Cavicchioli F, Shia A, O'Leary K, Haley V, Crook T, Thompson AM, Lackner M, Jones LJ et al. ( 2013 ) . Sensitivity to glutamine deprivation is dependent on the interplay between epigenetic regulation of Glutamine synthetase (Glul) and induction of autophagy . EUROPEAN JOURNAL OF CANCER . vol. 49 , S141 - S141 .
Coombes RC, Cardoso F, Isambert N, Lesimple T, Soulié P, Peraire C, Fohanno V, Kornowski A et al. ( 2013 ) . A phase i dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer . Breast Cancer Research and Treatment vol. 140 , ( 1 ) 73 - 82 .
Cope S, Ouwens MJNM, Jansen JP, Schmid P ( 2013 ) . Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: A network meta-analysis with parametric survival models . Value in Health vol. 16 , ( 2 ) 403 - 417 .
Eder B, Hofmann P, Hödl R, Wonisch M, Schmid P, Pokan R ( 2013 ) . Cardiac rehabilitation effective in elderly patients? . Journal fur Kardiologie vol. 20 , ( 9-10 ) 262 - 268 .
Aad G, Abajyan T, Abbott B, Abdallah J, Khalek SA, Abdelalim AA, Abdinov O, Aben R et al. ( 2012 ) . A Particle Consistent with the Higgs Boson Observed with the ATLAS Detector at the Large Hadron Collider . SCIENCE vol. 338 , ( 6114 ) 1576 - 1582 .
Cavicchioli F, Shia A, O'Leary K, Haley V, Crook T, Thompson A, Lackner M, Lo NC et al. ( 2012 ) . Abstract P4-06-10: Epigenetic silencing of glutamine synthetase (Glul) defines glutamine depletion therapy . Cancer Research . vol. 72 ,
Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E et al. ( 2012 ) . Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05) . Lung Cancer vol. 78 , ( 3 ) 239 - 244 .
Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D et al. ( 2012 ) . The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma . British Journal of Cancer vol. 107 , ( 8 ) 1423 - 1432 .
Aad G, Abajyan T, Abbott B, Abdallah J, Abdel Khalek S, Abdelalim AA, Abdinov O, Aben R et al. ( 2012 ) . Observation of a new particle in the search for the Standard Model Higgs boson with the ATLAS detector at the LHC . Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics vol. 716 , ( 1 ) 1 - 29 .
Cavicchioli F, Shia A, O'Leary K, Haley V, Palmieri C, Syed N, Crook T, Thompson AM et al. ( 2012 ) . 1660P Epigenetic Silencing of Arginino-Succinate Synthase (ASS1) Defines Arginine Depletion Therapy as a Novel Treatment Strategy for Breast Cancer . Annals of Oncology vol. 23 , ix532 - ix533 .
O'Leary K, Shia A, Haley V, Cavicchioli F, Comino A, Vanella P, Wischnewsky M, Crook T et al. ( 2012 ) . 169O Identification of Endoglin (CD105) as an Epigenetically Regulated Candidate Tumour Suppressor Gene in Lung Cancer . Annals of Oncology vol. 23 , ix73 - ix74 .
Cavicchioli F, Shia A, O'Leary K, Haley V, Palmieri C, Syed N, Crook T, Thompson AM et al. ( 2012 ) . EPIGENETIC SILENCING OF ARGININO-SUCCINATE SYNTHASE (ASS1) DEFINES ARGININE DEPLETION THERAPY AS A NOVEL TREATMENT STRATEGY FOR BREAST CANCER . ANNALS OF ONCOLOGY . vol. 23 , 532 - 533 .
O'Leary K, Shia A, Haley V, Cavicchioli F, Comino A, Vanella P, Wischnewsky M, Crook T et al. ( 2012 ) . IDENTIFICATION OF ENDOGLIN (CD105) AS AN EPIGENETICALLY REGULATED CANDIDATE TUMOUR SUPPRESSOR GENE IN LUNG CANCER . ANNALS OF ONCOLOGY . vol. 23 , 73 - 74 .
Wonisch M, Marko C, Niebauer J, Pokan R, Schmid P, Wiesinger E ( 2012 ) . Resistance training for patients with cardiovascular diseases . Wiener Klinische Wochenschrift vol. 124 , ( 9-10 ) 326 - 333 .
Berent R, Von Duvillard SP, Crouse SF, Auer J, Green JS, Niebauer J, Sinzinger H, Schmid P ( 2012 ) . Discontinuation of combined resistance-endurance training increases cardiovascular risk factors . International Journal of Cardiology vol. 156 , ( 2 ) 229 - 231 .
Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Wur̈schmidt F, Petry KU, Kimmig R et al. ( 2011 ) . Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: Results of the NOGGO-AGO intergroup study . Journal of Clinical Oncology vol. 29 , ( 28 ) 3791 - 3797 .
Berent R, Von Duvillard SP, Crouse SF, Sinzinger H, Green JS, Schmid P ( 2011 ) . Resistance training dose response in combined endurance-resistance training in patients with cardiovascular disease: A randomized trial . Archives of Physical Medicine and Rehabilitation vol. 92 , ( 10 ) 1527 - 1533 .
Nigro CL, Syed N, Lattanzio L, Dasoula A, Papoudou-Bai A, Schmid P, Merlano M, Hatzimichael E et al. ( 2011 ) . 1037 POSTER The Prolyl-3-hydroxylases (P3H) and P3H-related Genes CRTAP and SC65 Are Novel Transcriptionally Silenced Genes in Burkitt's Lymphoma . European Journal of Cancer . vol. 47 ,
Berent R, Auer J, Franklin B, Schmid P, Von Duvillard SP ( 2011 ) . Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period . American Journal of Cardiology vol. 108 , ( 5 ) 644 - 650 .
Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Ohashi Y et al. ( 2011 ) . Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials . The Lancet vol. 378 , ( 9793 ) 771 - 784 .
Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Smith DA, Yancey LJ, Crump M et al. ( 2011 ) . High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: Overview of six randomized trials . Journal of Clinical Oncology vol. 29 , ( 24 ) 3224 - 3231 .
Eggeman H, Stöblen F, Thill M, Korlach S, Schmid P, Lüftner D, Elling D, Taran FA et al. ( 2011 ) . Influence of a dose-dense adjuvant chemotherapy on sVCAM-1/sICAM-1 serum levels in breast cancer patients with 1-3 positive lymph nodes . Anticancer Research vol. 31 , ( 8 ) 2617 - 2622 .
Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU et al. ( 2011 ) . Prognostic significance of angiogenic factors in uterine cervical cancer . Anticancer Research vol. 31 , ( 8 ) 2589 - 2595 .
Lo Nigro C, Lattanzio L, Monteverde M, Syed N, Thompson AM, Garrone O, Cavicchioli F, Tonissi F et al. ( 2011 ) . The frequency of methylation of the NT5E gene in metastatic breast cancer . Journal of Clinical Oncology . vol. 29 , e11553 - e11553 .
Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, Blagden SP et al. ( 2011 ) . Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer . Cancer Res vol. 71 , ( 9 ) 3317 - 3327 .
White S, Harvey R, Mitchell H, Schmid P, Seckl M, Savage P ( 2011 ) . Characterisation of transient benign hCG elevations in women following chemotherapy for GTT . Journal of Obstetrics and Gynaecology vol. 31 , ( 2 ) 169 - 172 .
SCHMID-ARAYA J, Figueroa Hernandez D, Schmid PE, Drouot C ( 2011 ) . Algivory in food webs of three temperate Andean rivers . Austral Ecology
Berent R, Auer J, Schmid P, Krennmair G, Crouse SF, Green JS, Sinzinger H, Von Duvillard SP ( 2011 ) . Periodontal and coronary heart disease in patients undergoing coronary angiography . Metabolism: Clinical and Experimental vol. 60 , ( 1 ) 127 - 133 .
Huber K, Saely CH, Drexel H, Francesconi M, Gaul G, Glehr R, Lang IM, Marko C et al. ( 2011 ) . Practical implementation of guidelines for lipid lowering . Journal fur Kardiologie vol. 18 , ( 3-4 ) 96 - 99 .
Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al. ( 2010 ) . Drift Time Measurement in the ATLAS Liquid Argon Electromagnetic Calorimeter using Cosmic Muons . EUR PHYS J C vol. 70 , ( 3 ) 755 - 785 .
Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al. ( 2010 ) . Readiness of the ATLAS liquid argon calorimeter for LHC collisions . EUR PHYS J C vol. 70 , ( 3 ) 723 - 753 .
Lo Nigro C, Syed N, Lattanzio L, Dasoula A, Monteverde M, Hatzimichael E, Papoudou-Bai A, Schmid P et al. ( 2010 ) . P3H COLLAGEN PROLYL HYDROXYLASES ARE TISSUE SELECTIVE TUMOUR SUPPRESSORS . ANNALS OF ONCOLOGY . vol. 21 , 42 - 43 .
Jehn CF, Kühnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, Flath BC, Lüftner D ( 2010 ) . Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer . Integrative Cancer Therapies vol. 9 , ( 3 ) 270 - 275 .
Oguogho A, Efthimiou Y, Iliopoulos J, Stomatopoulos J, Ahmadzadehfar H, Schmid P, Steinbrenner D, Sinzinger H ( 2010 ) . Prickly pear changes <sup>111</sup>indium?LDL and <sup>111</sup>indium-HDL platelet binding correlating to improvement of platelet function in hypercholesterolemia . Journal of the Professional Association for Cactus Development vol. 12 , 67 - 79 .
Blackhall FH, Obrien M, Schmid P, Nicolson M, Taylor P, Milenkova T, Kennedy SJ, Thatcher N ( 2010 ) . A phase i study of vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer . Journal of Thoracic Oncology vol. 5 , ( 8 ) 1285 - 1288 .
Berent R, Auer J, Von Duvillard SP, Sinzinger H, Schmid P ( 2010 ) . Complications during exercise testing . Herz vol. 35 , ( 4 ) 267 - 272 .
Schmid P, Fleischmann C, Wischnewsky M, Syed N, Shah R, Quinlan P, Tooth L, Kuemmel S et al. ( 2010 ) . Use of prolyl 3-hydroxylases (P3H) to predict endocrine sensitivity in primary breast cancer . Journal of Clinical Oncology . vol. 28 , 592 - 592 .
Aad G, Abat E, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B et al. ( 2010 ) . Charged-particle multiplicities in pp interactions at √ s = 900 GeV measured with the ATLAS detector at the LHC . Physics Letters, Section B: Nuclear, Elementary Particle and High-Energy Physics vol. 688 , ( 1 ) 21 - 42 .
Schmid PE, Schmid-Araya JM ( 2010 ) . Scale-dependent relations between bacteria, organic matter and invertebrates in a headwater stream . FUND APPL LIMNOL vol. 176 , ( 4 ) 365 - 375 .
McGrath S, Short D, Harvey R, Schmid P, Savage PM, Seckl MJ ( 2010 ) . The management and outcome of women with post-hydatidiform mole low-risk gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l<sup>-1</sup> . British Journal of Cancer vol. 102 , ( 5 ) 810 - 814 .
Blohmer JU, Schmid P, Hilfrich J, Friese K, Kleine-Tebbe A, Koelbl H, Sommer H, Morack G et al. ( 2010 ) . Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: Final results of a randomised phase III trial . Annals of Oncology vol. 21 , ( 7 ) 1430 - 1435 .
Berent R, Auer J, Von Duvillard S, Sinzinger H, Steinbrenner D, Schmid P ( 2010 ) . Acute myocardial infarction with ST segment elevation in inferior and anterior leads: Right ventricular infarction . BMJ Case Reports
Berent R, von Duvillard SP, Auer J, Sinzinger H, Schmid P ( 2010 ) . Lack of supervision after residential cardiac rehabilitation increases cardiovascular risk factors . European Journal of Preventive Cardiology vol. 17 , ( 3 ) 296 - 302 .
Davidson N, Gelber R, Piccart M, Pruneri G, Pritchard K, Ravdin P, Robertson J, Swain S et al. ( 2010 ) . Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast . Journal of the National Cancer Institute - Monographs vol. 41 , 162 - 177 .
Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi B, Abolins M et al. ( 2009 ) . The ATLAS Collaboration . Nuclear Physics A . vol. 830 , 925c - 940c .
Schmid P, Kiewe P, Possinger K, Korfel A, Lindemann S, Giurescu M, Reif S, Wiesinger H et al. ( 2009 ) . Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors . Annals of Oncology vol. 21 , ( 3 ) 633 - 639 .
Nicholson LJ, Smith PR, Hiller L, Szlosarek PW, Kimberley C, Sehouli J, Koensgen D, Mustea A et al. ( 2009 ) . Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer . Int J Cancer vol. 125 , ( 6 ) 1454 - 1463 .
Schmid P, Nagai Y, Agarwal R, Hancock B, Savage PM, Sebire NJ, Lindsay I, Wells M et al. ( 2009 ) . Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study . The Lancet vol. 374 , ( 9683 ) 48 - 55 .
Schmid P, Krocker J, Kreienberg R, Klare P, Kittel K, Sommer H, Heinrich G, Steck T et al. ( 2009 ) . Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: Final results of a phase II trial . Cancer Chemotherapy and Pharmacology vol. 64 , ( 2 ) 401 - 406 .
Kuemmel S, Thomas A, Landt S, Fuger A, Schmid P, Kriner M, Blohmer JU, Sehouli J et al. ( 2009 ) . Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer . Anticancer Research vol. 29 , ( 2 ) 641 - 645 .
Berent R, Von Duvillard SP, Crouse SF, Auer J, Green JS, Sinzinger H, Schmid P ( 2009 ) . Short-term residential cardiac rehabilitation reduces B-type natriuretic peptide . European Journal of Cardiovascular Prevention and Rehabilitation vol. 16 , ( 5 ) 603 - 608 .
Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ et al. ( 2009 ) . Third consensus on medical treatment of metastatic breast cancer . Annals of Oncology vol. 20 , ( 11 ) 1771 - 1785 .
Wonisch M, Berent R, Klicpera M, Laimer H, Marko C, Pokan R, Schmid P, Schwann H ( 2008 ) . Practice guidelines for exercise testing . Journal fur Kardiologie vol. 15 , ( SUPPL. A ) 3 - 17 .
Harvey RA, Pursglove HD, Schmid P, Savage PM, Mitchell HDC, Seckl MJ ( 2008 ) . Human chorionic gonadotropin free β-subunit measurement as a marker of placental site trophoblastic tumors . Journal of Reproductive Medicine for the Obstetrician and Gynecologist vol. 53 , ( 8 ) 643 - 648 .
Lim AKP, Patel D, Patel N, Hawtin K, Dayal L, Schmid P, Savage P, Seckl MJ ( 2008 ) . Pelvic imaging in gestational trophoblastic neoplasia . Journal of Reproductive Medicine for the Obstetrician and Gynecologist vol. 53 , ( 8 ) 575 - 578 .
Aad G, Abat E, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O, Abi BA, Abolins M et al. ( 2008 ) . The ATLAS Experiment at the CERN Large Hadron Collider . J INSTRUM vol. 3 , Article S08003 ,
Schmid P, Kühnhardt D, Kiewe P, Lehenbauer-Dehm S, Schippinger W, Greil R, Lange W, Preiss J et al. ( 2008 ) . A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines . Annals of Oncology vol. 19 , ( 5 ) 871 - 876 .
Syed N, Coley H, Sehouli J, Koensgen D, Mustea A, Slozarek P, McNeish I, Schmid P et al. ( 2008 ) . Methylation reversal reveals Snk/PLK2 as a critical determinant of clinical outcome in ovarian cancer . CANCER RESEARCH . vol. 68 ,
Fürstenberger G, Schmid P, Duquesne A, Ammann M, Senn HJ ( 2008 ) . Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapy . Cancer Chemotherapy and Pharmacology vol. 61 , ( 2 ) 347 - 348 .
Wang J, Short D, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Seckl MJ ( 2008 ) . Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/ etoposide (TP/TE) . Annals of Oncology vol. 19 , ( 9 ) 1578 - 1583 .
Schmid P ( 2007 ) . Bisphosphonate for the treatment of tumor induced in bone changes . Onkologe vol. 13 , ( 7 ) 609 - 618 .
Colleoni M, Gelber S, Simoncini E, Pagani O, Gelber RD, Price KN, Castiglione-Gertsch M, Coates AS et al. ( 2007 ) . Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: Results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93 . Annals of Oncology vol. 18 , ( 7 ) 1177 - 1184 .
Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L et al. ( 2007 ) . Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: The TABLE study . Journal of Clinical Oncology vol. 25 , ( 18 ) 2509 - 2515 .
Schmid P ( 2007 ) . High-dose chemotherapy for breast cancer . Onkologe vol. 13 , ( 5 ) 409 - 424 .
Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, Pappin C, Schmid P et al. ( 2007 ) . A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia . British Journal of Cancer vol. 96 , ( 5 ) 732 - 737 .
Kümmel S, Rezai M, Kimmig R, Schmid P ( 2007 ) . Dose-dense chemotherapy for primary breast cancer . Current Opinion in Obstetrics and Gynecology vol. 19 , ( 1 ) 75 - 81 .
Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J et al. ( 2007 ) . Second consensus on medical treatment of metastatic breast cancer . Annals of Oncology vol. 18 , ( 2 ) 215 - 225 .
Kümmel S, Eggemann H, Lüftner D, Gebauer N, Bühler H, Schaller G, Schmid P, Kreienberg R et al. ( 2007 ) . Significant changes in circulating plasma levels of IGF1 and IGFBP3 after conventional or dose-intensified adjuvant treatment of breast cancer patients with one to three positive lymph nodes . International Journal of Biological Markers vol. 22 , ( 3 ) 186 - 193 .
Powles T, Young A, Sanitt A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . Erratum: The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours (British Journal of Cancer (2006) 95, (1145-1147) DOI: 10.1038/sj.bjc.6603416) . British Journal of Cancer vol. 95 , ( 12 )
Jehn CF, Kuehnhardt D, Bartholomae A, Pfeiffer S, Krebs M, Regierer AC, Schmid P, Possinger K et al. ( 2006 ) . Biomarkers of depression in cancer patients . Cancer vol. 107 , ( 11 ) 2723 - 2729 .
Possinger K, Schmid P ( 2006 ) . Chemotherapy for metastatic breast cancer . Zentralblatt fur Gynakologie vol. 128 , ( 6 ) 318 - 326 .
Schmid P ( 2006 ) . Mechanism of action and application possibilities: Adjuvant hormonal therapy of breast carcinoma . Best Practice Onkologie vol. 1 , ( 1 ) 42 - 57 .
Powles T, Young A, Sammit A, Stebbing J, Short D, Bower M, Savage PM, Seckl MJ et al. ( 2006 ) . The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours . British Journal of Cancer vol. 95 , ( 9 ) 1145 - 1147 .
Dhillon T, Palmieri C, Sebire NJ, Lindsay I, Newlands ES, Schmid P, Savage PM, Frank J et al. ( 2006 ) . Value of whole body <sup>18</sup>FDG-PET to identify the active site of gestational trophoblastic neoplasia . Journal of Reproductive Medicine for the Obstetrician and Gynecologist . vol. 51 , 879 - 887 .
Murugaesu N, Schmid P, Dancey G, Agarwal R, Holden L, McNeish I, Savage PM, Newlands ES et al. ( 2006 ) . Malignant ovarian germ cell tumors: Identification of novel prognostic markers and long-term outcome after multimodality treatment . Journal of Clinical Oncology vol. 24 , ( 30 ) 4862 - 4866 .
Pokan R, Hofmann P, Von Duvillard SP, Smekal G, Wonisch M, Lettner K, Schmid P, Shechter M et al. ( 2006 ) . Oral magnesium therapy, exercise heart rate, exercise tolerance, and myocardial function in coronary artery disease patients . British Journal of Sports Medicine vol. 40 , ( 9 ) 773 - 778 .
Powles T, Young A, Short D, Savage P, Pappin C, Schmid P, Seckl M ( 2006 ) . The outcome of patients with relapsed gestational trophoblastic neoplasm (GTN) after the completion of chemotherapy . J Clin Oncol vol. 24 , ( 18_suppl )
Kümmel S, Eggemann H, Lüftner D, Thomas A, Jeschke S, Zerfel N, Heilmann V, Emons G et al. ( 2006 ) . Changes in the circulating plasma levels of VEGF and VEGF-D after adjuvant chemotherapy in patients with breast cancer and 1 to 3 positive lymph nodes . Anticancer Research . vol. 26 , 1719 - 1726 .
Kümmel S, Elling D, Jeschke S, Schmid P, Thomas A ( 2006 ) . Chemotherapy treatment options for elderly women with breast cancer . Anticancer Research . vol. 26 , 1673 - 1676 .
Schmid P, Schippinger W, Nitsch T, Huebner G, Heilmann V, Schultze W, Hausmaninger H, Wischnewsky M et al. ( 2005 ) . Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: Results of a randomized trial . Journal of Clinical Oncology vol. 23 , ( 3 ) 432 - 440 .
Schmid P, Heilmann V, Schulz CO, Dieing A, Lehenbauer-Dehm S, Jehn C, Sezer O, Possinger K et al. ( 2005 ) . Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: A phase II study . Journal of Cancer Research and Clinical Oncology vol. 131 , ( 9 ) 568 - 574 .
Schmid P, Flath B, Akrivakis K, Heilmann V, Mergenthaler HG, Sezer O, Kreienberg R, Possinger K ( 2005 ) . Gemcitabine and mitoxantrone in metastatic breast cancer: A phase-I-study . Investigational New Drugs vol. 23 , ( 4 ) 349 - 356 .
Schmid P, Possinger K ( 2005 ) . Gemcitabin (Gemzar) . Gynakologische Praxis vol. 29 , ( 2 ) 351 - 358 .
Schmid P, Possinger K ( 2005 ) . Gemcitabine (Gemzar) . Internistische Praxis vol. 45 , ( 2 ) 415 - 422 .
Schmid P, Possinger K ( 2005 ) . Gemcitabin (Gemzar) . Padiatrische Praxis vol. 66 , ( 3 ) 521 - 528 .
Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K et al. ( 2005 ) . Proteasome: An emerging target for cancer therapy . Anti-Cancer Drugs vol. 16 , ( 5 ) 475 - 481 .
Stead TK, Schmid-Araya JM, Schmid PE, HILDREW AG ( 2005 ) . The distribution of body size in a stream community: one system, many patterns . Journal of Animal Ecology vol. 74 , ( 3 ) 475 - 487 .
Schmid P, Possinger K ( 2005 ) . Gemcitabin (Gemzar) . Chirurgische Praxis vol. 64 , ( 2 ) 351 - 358 .
Schmid P, Schweigert M, Beinert T, Flath B, Sezer O, Possinger K ( 2005 ) . Prolonged infusion of gemcitabine in advanced solid tumors: A phase-I-study . Investigational New Drugs vol. 23 , ( 2 ) 139 - 146 .
Schmid P, Krocker J, Jehn C, Michniewicz K, Lehenbauer-Dehm S, Eggemann H, Heilmann V, Kümmel S et al. ( 2005 ) . Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: Final results of a phase II trial . Annals of Oncology vol. 16 , ( 10 ) 1624 - 1631 .
Schmid P, Krocker J, Schulz CO, Michniewicz K, Dieing A, Eggemann H, Heilmann V, Blohmer JU et al. ( 2005 ) . Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: Results of a phase I trial . Anti-Cancer Drugs vol. 16 , ( 1 ) 21 - 29 .
Pokan R, Von Duvillard SP, Ludwig J, Rohrer A, Hofmann P, Wonisch M, Smekal G, Schmid P et al. ( 2004 ) . Effect of high-volume and -intensity endurance training in heart transplant recipients . Medicine and Science in Sports and Exercise vol. 36 , ( 12 ) 2011 - 2016 .
Untch M, Kahlert S, Kosse V, Bondar G, Kienle E, Maubach L, Hillger H, Schmid P et al. ( 2004 ) . Leuprorelinacetate as a 3 month depot has the same efficacy as CMF in the adjuvant therapy of pre-perimenopausal, node positive breast cancer patients with positive receptor status - The TABLE study . Geburtshilfe und Frauenheilkunde vol. 64 , ( 12 ) 1316 - 1323 .
Dieing A, Schulz CO, Schmid P, Roever AC, Lehenbauer-Dehm S, Jehn C, Flath B, Possinger K ( 2004 ) . Orbital metastases in breast cancer: Report of two cases and review of the literature . Journal of Cancer Research and Clinical Oncology vol. 130 , ( 12 ) 745 - 748 .
Schmid P, Helmreich G, Gradauer L, Stowasser G, Bronnenmayer J, Pokan R ( 2004 ) . Are there non responders to exercise therapy after myocardial infarction? . Journal fur Kardiologie vol. 11 , ( 11 ) 453 - 457 .
Pokan R, Hofmann P, Wonisch M, Smekal G, Bachl N, Mayr K, Benzer W, Schmid P ( 2004 ) . Performance diagnostic and target training heart rate in cardiac rehabilitation . Journal fur Kardiologie vol. 11 , ( 11 ) 446 - 452 .
Höfer S, Benzer W, Brandt D, Laimer H, Schmid P, Bernardo A, Oldridge NB ( 2004 ) . MacNew Heart Disease Questionnaire after myocardial infarction: The German version . Zeitschrift fur Klinische Psychologie und Psychotherapie vol. 33 , ( 4 ) 270 - 280 .
Schmid P, Krocker J, Morack G, Heilmann V, Blohmer JU, Michniewicz K, Köhler G, Schaller-Kranz T et al. ( 2004 ) . Primary chemotherapy with doxorubicin and paclitaxel in patients with early breast cancer: Final results of a multicenter phase II study . Journal of Cancer Research and Clinical Oncology vol. 130 , ( 11 ) 657 - 663 .
Schmid P, Helmreich G, Gradauer L, Schmid F ( 2004 ) . Percutaneous transradial artery approach for coronary diagnostics and PCI . Journal fur Kardiologie vol. 11 , ( 9 ) 359 - 362 .
Pokan R, Wonisch M, Schmid P ( 2004 ) . Changes in the athlete's heart in the ECG . Internistische Praxis vol. 44 , ( 1 ) 79 - 88 .
Schmid P, Schmid F, Smekal G, Pokan R ( 2003 ) . Physical Activity and Primary Prevention . Journal fur Kardiologie vol. 10 , ( 12 ) 548 - 553 .
Beslija S, Bonneterre J, Burstein HJ, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler W et al. ( 2003 ) . Consensus on medical treatment of metastatic breast cancer . Breast Cancer Research and Treatment . vol. 81 ,
Lüftner D, Jung A, Schmid P, Geppert R, Kienle E, Wernecke KD, Possinger K ( 2003 ) . Upregulation of HER-2/neu by ovarian ablation: Results of a randomized trial comparing leuprorelin to CMF as adjuvant therapy in node-positive breast cancer patients . Breast Cancer Research and Treatment vol. 80 , ( 3 ) 245 - 255 .
Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, Sezer O ( 2003 ) . Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer . British Journal of Cancer vol. 88 , ( 9 ) 1406 - 1410 .
Schobersberger W, Schmid P, Lechleitner M, von Duvillard SP, Hörtnagl H, Gunga HC, Klingler A, Fries D et al. ( 2003 ) . Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome . European Journal of Applied Physiology vol. 88 , ( 6 ) 506 - 514 .
Schmid P, Possinger K ( 2003 ) . Bisphosphonates in metastatic breast cancer . Breast Cancer Research and Treatment . vol. 81 ,
Schmid P, Possinger K ( 2003 ) . Which treatment when? . Breast Cancer Research and Treatment . vol. 81 ,
Schmid P, Possinger K ( 2002 ) . Interactions of antioestrogens and aromatase inhibitors . FORUM - Trends in Experimental and Clinical Medicine vol. 12 , ( 1 ) 45 - 59 .
Schmid P, Wischnewsky MB, Sezer O, Böhm R, Possinger K ( 2002 ) . Prediction of response to hormonal treatment in metastatic breast cancer . Oncology vol. 63 , ( 4 ) 309 - 316 .
Schmid P, Possinger K ( 2002 ) . High-dose chemotherapy in breast cancer . Medizinische Klinik vol. 97 , ( 11 ) 677 - 686 .
Eucker J, Schille C, Schmid P, Jakob C, Schetelig J, Kingreen D, Mergenthaler HG, Huhn D et al. ( 2002 ) . The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas . Anti-Cancer Drugs vol. 13 , ( 9 ) 907 - 913 .
Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E et al. ( 2002 ) . Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: Preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate) . Anticancer Research vol. 22 , ( 4 ) 2325 - 2332 .
Schmid P, Possinger K ( 2002 ) . High-dose chemotherapy in high-risk primary breast cancer . Onkologie vol. 25 , ( 2 ) 112 - 120 .
Schmid P, Possinger K ( 2002 ) . Systemic therapy in breast cancer - Adjuvant and neo-adjuvant treatment: Update situation and update studies . Viszeralchirurgie vol. 37 , ( 2 ) 137 - 149 .
Schmid P, Possinger K ( 2002 ) . Adjuvant and neoadjuvant systemic therapy of breast cancer . Internist vol. 43 , ( 3 ) 341 - 353 .
Pokan R, Hofmann P, Smekal G, Wonisch M, Bachl N, Schmid P ( 2002 ) . Performance testing for regulating training in exercise therapy of cardiovascular disease . Internistische Praxis vol. 42 , ( 4 ) 797 - 806 .
Schmid P, Sezer O, Possinger K ( 2001 ) . Bisphosphonates in oncology . Pharmazie in Unserer Zeit vol. 30 , ( 6 ) 519 - 528 .
Schmid PE, Schmid-Araya JM ( 2001 ) . Editorial: Eine kritische Betrachtung zum Stand der Ökologischen Forschung . Environmental Sciences Europe vol. 13 , ( 5 ) 255 - 257 .
Schmid P, Fritz J, Possinger K ( 2001 ) . Treatment options for metastatic breast cancer . Internistische Praxis vol. 41 , ( 2 ) 319 - 332 .
Sezer O, Eucker J, Jakob C, Kaufmann O, Schmid P, Possinger K ( 2001 ) . Achievement of complete remission in refractory Hodgkin's disease with prolonged infussion of gemcitabine . Investigational New Drugs vol. 19 , ( 1 ) 101 - 104 .
Sinzinger H, Hoppichler F, Kritz H, Laimer H, Schmid P, Silberbauer K, Toplak H ( 2001 ) . HDL-2000 - Ein konsensus . Wiener Klinische Wochenschrift vol. 113 , ( 5-6 ) 212 - 214 .
Grosse Y, Schmid P, Possinger K ( 2001 ) . Bisphosphonates in the treatment of breast cancer. Prevention and adjuvant therapy . Tagliche Praxis vol. 42 , ( 4 ) 727 - 734 .
Pokan R, Pelikan J, Retzer H, Hofmann P, Von Duvillard SP, Smekal G, Wonisch M, Fruhwald FM et al. ( 2001 ) . Leistungsfähigkeit und herzfrequenz von patienten mit KHK im MAXLASS und deren zusammenhang mit dem herzfrequenzverhalten und der myokardialen funktion unter belastung im stufentest . Deutsche Zeitschrift fur Sportmedizin vol. 52 , ( 7-8 )
Schmid P, Possinger K ( 2001 ) . Liposomal anthracyclines for improved cardiac tolerability . Breast vol. 10 , ( SUPPL. 2 ) 22 - 27 .
Schmid P ( 2001 ) . Stellenwert der Bewegungstherapie in der Primär- und Sekundärprävention der KHK . Deutsche Zeitschrift fur Sportmedizin vol. 52 , ( 7-8 )
Lueftner DI, Schmid P, Kienle E, Possinger K ( 2001 ) . Upregulation of Her-2/neu under chemical castration: Serum results of a randomized trial comparing leuprorelin acetate to CMF for adjuvant therapy of nodal-positive breast cancer . Breast Cancer Research and Treatment vol. 69 , ( 3 )
Sezer O, Eucker J, Jakob C, Schmid P, Possinger K ( 2000 ) . Prolonged infusion of gemcitabine in refractory hodgkin's disease . Blood vol. 96 , ( 11 PART II )
Possinger K, Schmid P ( 2000 ) . Therapeutic possibilities in breast carcinoma . Onkologe . vol. 6 ,
Schmid PE, Tokeshi M, Schmid-Araya JM ( 2000 ) . Relation between population density and body size in stream communities . Science vol. 289 , ( 5484 ) 1557 - 1560 .
Schmid P, Possinger K ( 2000 ) . Advanced breast cancer. Palliative measures are becoming ever more tolerable . MMW-Fortschritte der Medizin vol. 142 , ( 35 ) 22 - 24 .
Possinger K, Schmid P ( 2000 ) . New drugs for the treatment of breast cancer . Onkologe vol. 6 , ( 5 ) 392 - 409 .
Böttner A, Pirro F, Schmid P, Traeder W, Weiskopf S, Weiss H, Zschiesche E ( 2000 ) . [Guidelines for planning studies to determine the resistance of infectious agents of veterinary relevance] . Berl Munch Tierarztl Wochenschr vol. 113 , ( 7-8 ) 299 - 305 .
Sinzinger H, Chehne F, Schmid P, Kritz H ( 2000 ) . Plasma homocysteine is not altered during simvastatin-therapy . Wiener Klinische Wochenschrift vol. 112 , ( 12 ) 540 - 543 .
Pokan R, Von Duvillard SP, Hofmann P, Smekal G, Fruhwald FM, Gasser R, Tschan H, Baron R et al. ( 2000 ) . Change in left atrial and ventricular dimensions during and immediately after exercise . Medicine and Science in Sports and Exercise vol. 32 , ( 10 ) 1713 - 1718 .
Sezer O, Langelotz C, Blohmer JU, Schmid P, Akrivakis K, Possinger K ( 2000 ) . Detection of HMGI-C in the peripheral blood of breast cancer patients . European Journal of Cancer vol. 36 , ( 15 ) 1944 - 1948 .
Beinert T, Binder D, Oehm C, Ziemer S, Priem F, Stuschke M, Schweigert M, Siebert G et al. ( 2000 ) . Further evidence for oxidant-induced vascular endothelial growth factor up-regulation in the bronchoalveolar lavage fluid of lung cancer patients undergoing radio-chemotherapy . Journal of Cancer Research and Clinical Oncology vol. 126 , ( 6 ) 352 - 356 .
Sezer O, Eucker J, Schmid P, Possinger K ( 2000 ) . New therapeutic approaches in primary systemic AL amyloidosis . Annals of Hematology vol. 79 , ( 1 ) 1 - 6 .
Sezer O, Schmid P, Hallek M, Schweigert M, Beinert T, Langelotz C, Mergenthaler HG, Possinger K ( 1999 ) . Eosinophila during fludarabine treatment of chronic lymphocytic leukemia . Annals of Hematology vol. 78 , ( 10 ) 475 - 477 .
Sinzinger H, Schmid P, O'Grady J ( 1999 ) . Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment [3] . Atherosclerosis vol. 143 , ( 2 ) 459 - 460 .
Helmreich G, Gradauer L, Schmid P ( 1999 ) . Duration and complications in diagnostic coronary angiography via the radial artery . Journal fur Kardiologie vol. 6 , ( 10-11 ) 545 - 549 .
Schmid P, Helmreich G, Gradauer L ( 1999 ) . Methods for diagnostic coronary angiography via the radial artery . Journal fur Kardiologie vol. 6 , ( 10-11 ) 538 - 542 .
Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG, Possinger K ( 1999 ) . Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer . Anti-Cancer Drugs vol. 10 , ( 7 ) 625 - 631 .
Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, Possinger K ( 1999 ) . Prolonged infusion of gemcitabine in stage IV breast cancer: A phase I study . Anti-Cancer Drugs vol. 10 , ( 6 ) 525 - 531 .
Sezer O, Schmid P, Schweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H et al. ( 1999 ) . Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support . Bone Marrow Transplantation vol. 23 , ( 9 ) 967 - 969 .
Pokan R, Hofmann P, Von Duvillard SP, Smekal G, Hogler R, Tschan H, Baron R, Schmid P et al. ( 1999 ) . The heart rate turn point reliability and methodological aspects . Medicine and Science in Sports and Exercise vol. 31 , ( 6 ) 903 - 907 .
Sezer O, Schmid P, Mergenthaler HG, Beinert T, Possinger K ( 1999 ) . Use of bisphosphonates in therapy and prophylaxis of cancer-induced bone diseases . Onkologie vol. 22 , ( 5 ) 400 - 404 .
Pokan R, Hofmann P, Von Duvillard SP, Beaufort F, Smekal G, Gasser R, Klein W, Eber B et al. ( 1998 ) . The heart rate performance curve and left ventricular function during exercise in patients after myocardial infarction . Medicine and Science in Sports and Exercise vol. 30 , ( 10 ) 1475 - 1480 .
Pokan R, Hofmann P, Von Duvillard SP, Schumacher M, Gasser R, Zweiker R, Fruhwald FM, Eber B et al. ( 1998 ) . Parasympathetic receptor blockade and the heart rate performance curve . Medicine and Science in Sports and Exercise vol. 30 , ( 2 ) 229 - 233 .
Hofmann P, Pokan R, Von Duvillard SP, Schmid P, Conconi F, Grazzi G, Casoni I, Borsetto C et al. ( 1997 ) . The Conconi test (multiple letters) [2] . International Journal of Sports Medicine vol. 18 , ( 5 ) 397 - 399 .
Pokan R, Hofmann P, Von Duvillard SP, Beaufort F, Schumacher M, Fruhwald FM, Zweiker R, Eber B et al. ( 1997 ) . Left ventricular function in response to the transition from aerobic to anaerobic metabolism . Medicine and Science in Sports and Exercise vol. 29 , ( 8 ) 1040 - 1047 .
Hofmann P, Pokan R, Bachl N, Schmid P ( 1997 ) . A short communication regarding the article by M. Kara et al. "Determination of the heart rate deflection point by the Dmax method." (J Sports Med Phys Fitness 1996;36(1):31-4) . The Journal of sports medicine and physical fitness vol. 37 , ( 2 ) 151 - 155 .
O'Grady J, Kritz H, Schmid P, Pirich C, Sinzinger H ( 1997 ) . Effect of isradipine on in-vivo platelet function . Thrombosis Research vol. 86 , ( 5 ) 363 - 371 .
Hofmann P, Pokan R, Von Duvillard SP, Seibert FJ, Zweiker R, Schmid P ( 1997 ) . Heart rate performance curve during incremental cycle ergometer exercise in healthy young male subjects . Medicine and Science in Sports and Exercise vol. 29 , ( 6 ) 762 - 768 .
Kritz H, Schmid P, Karanikas G, Rodrigues M, Sinzinger H ( 1997 ) . Detection of early atherosclerotic lesions in the carotid artery: Experimental and preliminary human data . International Journal of Angiology vol. 6 , ( 1 ) 24 - 29 .
Kritz H, Schmid P, Karanikas G, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H ( 1996 ) . Passive smoking increases platelet thromboxane . International Journal of Angiology vol. 5 , ( 3 ) 134 - 139 .
Hentrich MU, Brack NG, Schmid P, Schuster T, Clemm C, Hartenstein RC ( 1996 ) . Testicular germ cell tumors in patients with human immunodeficiency virus infection . Cancer vol. 77 , ( 10 ) 2109 - 2116 .
Benzer W, Schmid P, Maehr G, Drexel H ( 1996 ) . Effects of intravenous magnesium chloride reverses left ventricular end-diastolic pressure in coronary artery disease . American Journal of Cardiology vol. 77 , ( 8 ) 638 - 640 .
Schmid P, Karanikas G, Kritz H, Pirich C, Stamatopoulos Y, Peskar BA, Sinzinger H ( 1996 ) . Passive smoking and platelet thromboxane . Thrombosis Research vol. 81 , ( 4 ) 451 - 460 .
Otto F, Schmid P, Mackensen A, Wehr U, Seiz A, Braun M, Galanos C, Mertelsmann R et al. ( 1996 ) . Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer . European Journal of Cancer Part A vol. 32 , ( 10 ) 1712 - 1718 .
Sinzinger H, Kritz H, Virgolini I, Schmid P, Rogatti W ( 1996 ) . Prostaglandin E<inf>1</inf> increases binding of<sup>123</sup>l-low-density lipoprotein to the human liver in vivo . European Journal of Clinical Pharmacology vol. 49 , ( 6 ) 515 - 520 .
Kritz H, Schmid P, Keiler A, O'Grady J, Sinzinger H ( 1995 ) . Isradipine increases vascular prostaglandin I<inf>2</inf>-formation while the thromboxane B<inf>2</inf>-synthesis is diminished . Thrombosis Research vol. 80 , ( 6 ) 483 - 489 .
Benzer W, Schmid P ( 1995 ) . Rehabilitation after myocardial infarct--a multidisciplinary responsibility . Wiener klinische Wochenschrift vol. 107 , ( 24 )
Kritz H, Schmid P, Sinzinger H ( 1995 ) . Passive Smoking and Cardiovascular Risk . Archives of Internal Medicine vol. 155 , ( 18 ) 1942 - 1948 .
Pokan R, Hofmann P, Lehmann M, Leitner H, Eber B, Gasser R, Schwaberger G, Schmid P et al. ( 1995 ) . Heart rate deflection related to lactate performance curve and plasma catecholamine response during incremental cycle ergometer exercise . European Journal of Applied Physiology and Occupational Physiology vol. 70 , ( 2 ) 175 - 179 .
Sinzinger H, Mayr F, Schmid P, Granegger S, O'Grady J, Peskar BA ( 1994 ) . Sleep disturbance and appetite loss after lovastatin . The Lancet vol. 343 , ( 8903 )
Pirich C, Schmid P, Fitscha P, Wytek R, O'Grady J, Sinzinger H ( 1994 ) . Influence of calcium antagonists on platelet function and vascular prostacyclin production . Blood Pressure, Supplement . vol. 3 , 75 - 80 .
Pirich C, Fitscha P, Schmid P, Sinzinger H ( 1994 ) . Isradipine decreases the entry of radioiodine-labelled low-density lipoproteins into the arterial wall . Blood Pressure, Supplement . vol. 3 , 70 - 74 .
Schmid P, Pirich C, Fitscha P, Pesau B, Virgolini I, Sinzinger H ( 1994 ) . Isradipine increases platelet - Low-density lipoprotein binding: Evidence from ex-vivo studies in humans . Blood Pressure, Supplement . vol. 3 , 65 - 69 .
Sinzinger H, Schmid P, Pirich C, Virgolini I, Pesau B, Granegger S, O'Grady J ( 1992 ) . Treatment of hypercholesterolaemia in children . The Lancet vol. 340 , ( 8818 ) 548 - 549 .
Pirich C, Schmid P, Pidlich J, Sinzinger H ( 1992 ) . Cholesterol lowering by Anticholest® - a high-fiber guar-pectin drink . Wiener Klinische Wochenschrift vol. 104 , ( 11 ) 314 - 316 .
Collaboration A-B-C-L-O-S, Bosetti PC, Deden H, Deutschmann M, Fritze P, Grässler H, Hasert FJ, Morfin J et al. ( 1978 ) . Analysis of nucleon structure functions in CERN bubble chamber neutrino experiments . Nuclear Physics B vol. 142 , ( 1-2 ) 1 - 28 .
Collaboration A-B-C-L-O-S, Bosetti PC, Deden H, Deutschmann M, Fritze P, Grässler H, Hasert FJ, Morfin J et al. ( 1978 ) . Cross sections for neutrino and antineutrino neutral current interactions . Physics Letters B vol. 76 , ( 4 ) 505 - 511 .
Bosetti PC, Deden H, Deutschmann M, Fritze P, Grässler H, Krenz W, Morfin J, Schmitz P et al. ( 1978 ) . Observation of prompt neutrinos from 400 Gev proton-nucleus collisions . Physics Letters B vol. 74 , ( 1-2 ) 143 - 147 .
Bosetti PC, Deden H, Fritze P, Grässler H, Hasert FJ, Kirch D, Morfin J, Seyfert H et al. ( 1978 ) . Di-Lepton events in the BEBC narrow-band beam neutrino experiment . Physics Letters B vol. 73 , ( 3 ) 380 - 384 .
Collaboration A-B-C-L-O-S, Bosetti PC, Deden H, Deutschmann M, Fritze P, Grässler H, Hasert FJ, Morfin J et al. ( 1977 ) . Total cross sections for charged-current neutrino and antineutrino interactions in BEBC in the energy range 20–200 GeV . Physics Letters B vol. 70 , ( 2 ) 273 - 277 .
Collaboration A-B-B-C-C-H-W, Grässler H, Schmitz P, Seyfert HH, Böttcher H, Klabuhn J, Lanius K, Naumann T et al. ( 1977 ) . Production and decay of the Δ(970) and D(1285) mesons in π±p interactions at 16 GeV/c . Nuclear Physics B vol. 121 , ( 2 ) 189 - 209 .
Collaboration A-B-B-C-C-H-W, Deutschmann M, Honecker R, Kirk H, Klein M, Nahnhauer R, Hartmann R, Plothow H et al. ( 1976 ) . Determination of the fire-ball dimensions from second-order interference between two pions . Nuclear Physics B vol. 103 , ( 2 ) 198 - 212 .
Collaboration A-B-C-L-V, Lauscher P, Otter G, Wieczorek H, Matthäus E, Schreiber HJ, Cocconi VT, Counihan MJ et al. ( 1975 ) . Spin-parity structure of the (Kπ) system produced in the reaction K−p → (K−π+)n . Nuclear Physics B vol. 86 , ( 2 ) 189 - 200 .
Herring H, Schmid P, Savill M ( 1957 ) . Beggars on Golden Stools. Report on Latin America . Hispanic American Historical Review vol. 37 , ( 2 )
KIRCHHOFF HW ( 1955 ) . Differential diagnosis of paramediastinal shadows in the right upper lobe from pleuritis mediastinalis superior . Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin vol. 82 , ( 5 ) 637 - 641 .